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1General introduction
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Allergic asthma
Allergic asthma affects at least 5% of adults and 10  - 15% of children in
westernized countries (1). Characteristics of the disease include reversible airflow
obstruction and increased airway responsiveness to a variety of stimuli. They are
associated with airway inflammation in which eosinophils, mast cells, and
lymphocytes, together with a multitude of cytokines and other signaling molecules,
are important players (2). Allergen exposure of people at risk of developing asthma
results in an inflammatory cascade that is initiated by dendritic cells. They are
abundantly present in the submucosa of asthmatic airways and are essential for the
uptake of allergens (3). After taking up allergen, dendritic cells migrate to local
lymph nodes where they present the allergen to T-cells that subsequently
differentiate into Th2 cells. These cells then secrete the cytokines that induce
proliferation of, and IgE production by allergen-recognizing B cells. Antigen-
specific IgE is bound by receptors on the cell surface of mast cells. Subsequent
cross-linking of mast cell-bound IgE upon re-exposure to allergen induces release of
mediators by the cells (see (4) for a review). Such mediators include histamine,
prostaglandin D2, and leukotrienes C4, D4, and E4 (5). In general, mast cell-derived
mediators produce airway constriction, increase microvascular permeability,
enhance airway smooth muscle responsiveness and promote recruitment of
eosinophils. In addition to secreting rapidly acting mediators, activated mast cells,
together with T cells, release a variety of cytokines, promoting the chronic features
of inflammation after allergen exposure, as reviewed in (6). These cytokines induce
recruitment of eosinophils and lymphocytes to the airways and promote their
survival and activation. In addition, a number of chemokines that attract and activate
inflammatory cells are produced by structural airway cells such as epithelial and
endothelial cells and fibroblasts (7), as well as smooth muscle cells (8). Thus, a
variety of events are involved in triggering and maintaining an allergic
inflammatory response in the airways, leading to the chronic inflammatory airway
disease, clinically defined as allergic asthma.
Asthma and reactive oxygen species
A variety of cells in the lungs of asthmatics is capable of producing large amounts
of reactive oxygen species (ROS). Activated eosinophils, neutrophils, monocytes,
and macrophages can produce superoxide (O2.-) (9). Subsequent dismutation of O2.-
yields hydrogen peroxide (H2O2). Indeed, H2O2 levels in exhaled air are higher in
asthmatics than in normals, and can be decreased by corticosteroid treatment (10).
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Although both O2.- and H2O2 are only moderate oxidants, they can become
potentially deleterious through their reactions with other molecules. For instance,
hydroxyl radical (OH.) is a very powerful oxidant and requires O2.- for its formation.
H2O2 is used as a substrate by myeloperoxidase (MPO) in neutrophils and
monocytes (11), or eosinophil peroxidase (EPO) in eosinophils (12) to produce the
highly oxidative hypohalous acids (HOCl and HOBr).
ROS, which may be radicals or non-radicals, serve in cell signaling as messenger
molecules (13) and in host defense, as killers of pathogens or tumor cells (14).
However, in case of a poorly functioning antioxidant system or if ROS are produced
in excessive amounts, they may become harmful to host tissue, ultimately leading to
tissue injury and inflammation (15). Indeed, the influx and activation of eosinophils
into the lungs of asthmatics can induce substantial oxidative damage (16). Notably,
eosinophils can generate more O2.- and H2O2 than neutrophils, and their EPO
content is higher than the MPO content of neutrophils (17). In addition to recruited
inflammatory cells, the structural airway cells such as epithelial cells can also be
potent sources of ROS (18).
The inflammatory cells recruited to the asthmatic airways produce larger amounts of
free radicals upon stimulation in vitro than do leukocytes obtained from healthy
subjects (for a review, see (19)).  The resulting oxidative stress may render airway
smooth muscle hyperreactive to contractile stimuli (20), while long-term oxidative
stress may play a role in airway remodeling in asthma (9). Exogenous sources of
ROS may also induce airway hyperreactivity. For instance, ozone exposure renders
guinea pig airways hyperreactive to methacholine (21) and increases the airway
hyperreactivity of mild asthmatics (22). Hyperoxia induces airway hyperreactivity in
neonatal guinea pigs, which is thought to mimic the hyperresponsiveness generated
by hyperoxia during the treatment of respiratory distress syndrome (23).
Asthma and antioxidants
The lungs have a variety of both enzymatic and non-enzymatic antioxidant tools to
combat oxidative stress. Numerous studies have addressed potential disturbances of
anti-oxidant systems in asthma, but their outcomes are not always unambiguous. For
instance, superoxide dismutase (SOD) activity was found to be similar in broncho-
alveolar lavage (BAL) fluid of normals and asthmatics (24), higher in asthmatics
than in normals (25), and lower in asthmatic BAL cells and bronchial epithelial cells
as compared to those of normals (26). The findings pertaining to other antioxidant
systems are less conflicting. Several publications have demonstrated that asthmatics
have lower levels of selenium, required for glutathione peroxidase function (27-29).
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Insufficient dietary intake of antioxidant vitamins by asthmatics has been reported
(30-33), as well as low levels of vitamins C and E in their lungs (34). The
antioxidant, glutathione, and its levels in asthmatics are addressed in separate
sections below.
Glutathione
Glutathione (GSH, L-γ-glutamyl-L-cysteinylglycine) is the most abundant non-
protein thiol in mammalian cells and a major (airway) antioxidant (35). As a
substrate for GSH S-transferase, it is involved in the detoxification of xenobiotic
compounds. More relevant to this thesis is the role of GSH as a substrate of GSH
peroxidase in the detoxification of ROS and free radicals. These are also detoxified
by GSH in non-enzymatic reactions. When participating in antioxidant reactions,
two molecules of GSH react to form the disulfide, oxidized glutathione (GSSG).
GSSG is readily reduced by glutathione reductase under normal conditions, so that
tissue concentrations of GSSG are normally less than 3 to 5% of the total (GSH +
GSSG) glutathione concentrations in the body (36). However, in conditions of
oxidative stress, this balance may be disturbed. Therefore, the relative amount of
GSSG is often taken as an indicator of oxidative stress.
GSH metabolism
As outlined in figure 1, cellular GSH synthesis takes place in the cytosol in two
steps. In the first, rate-limiting step, γ-glutamylcysteine is formed from γ-glutamic
acid and cysteine by γ-glutamylcysteine synthetase. In the second step, GSH
synthetase catalyses the reaction between γ-glutamylcysteine and glycine to form
GSH. Maximum cytosolic concentrations of GSH are limited via feedback
inhibition of the first reaction step by GSH itself.
The γ-glutamyl bond in GSH makes the molecule resistant to intracellular
peptidases. However, this bond can be cleaved by γ-glutamyl transpeptidase, an
enzyme located on the external cell membrane of cells in various tissues, including
lung tissue (37, 38). As indicated by Berggren et al. (39), γ-glutamyl transpeptidase
is essential for the use of extracellular GSH to maintain cytosolic levels of GSH in
lung tissue. Their studies in isolated and perfused rat lung showed that lung tissue
utilizes plasma GSH in a process of extracellular breakdown and cytosolic
resynthesis, rather than by direct uptake. The importance of GSH in the lung was
further demonstrated by Martensson, who calculated that about 200 nmol/min of
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GSH is taken up from plasma during transit through murine lung. For comparison,
this value has been estimate to be 50 nmol/min in mouse kidney (37), another organ
with a high GSH consumption (40).
Depletion of cellular GSH as a research tool
To study the role of GSH and GSH synthesis, experimental induction of GSH
deficiency is a valuable tool. Several ways have been described to deplete GSH (for
a review, see (41)). One way is to expose tissues to oxidizing agents such as diamide
or t-butylhydroperoxide. Other strategies are the use of compounds that react with
the thiol group of GSH, such as diethyl maleate and phorone. Both strategies,
however, have disadvantages due to their toxic side effects and lack of specificity.
The most specific way to deplete GSH is the use of amino acid sulfoximines, which
are inhibitors of the rate-limiting enzyme in GSH synthesis, γ-glutamylcysteine
synthetase (figure 1). Although several sulfoximines are known, buthionine
sulfoximine is most frequently used because of its low toxicity compared to the
other compounds of its class.
Glutathione
synthetase
GSH
GSH cys - gly   + γ-glutamic acid 
γ-glutamyl
transpeptidase
γ-glutamic acid
γ-glu-cys
synthetase
cys + ATP
γ-glu-cys
gly + ATP
_
BSO
cell membrane
intracellular
extracellular
Figure 1. GSH synthesis. Modified from (48).
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GSH and nitric oxide
The thiol (-SH) group of GSH accounts for most, if not all of the specific properties
of the molecule. One of them is the capacity of GSH to bind the (airway) smooth
muscle relaxant, (42) nitric oxide (NO), to form S-nitrosoglutathione (GSNO).
Genuine NO has a short half life in biological systems, and GSNO is thought to act
as a stable reservoir of NO. Although GSNO is often referred to as a NO-donor, the
genuine compound has smooth muscle relaxing properties, similar to those of NO.
The interactions of nitric oxide with thiol groups have recently been outlined in an
excellent review by Gaston (43).
Glutathione in asthma
Physiologic GSH levels in alveolar lining fluid are about 400 μM, which is more
than 100-fold higher than in blood plasma (44). Smith et al. have reported higher
levels of glutathione in lining fluid of mild asthmatics than normals (24), but they
made no distinction between GSH and GSSG. The increased levels of total
glutathione may result from a rebound effect after an episode of oxidative stress.
Indeed, when alveolar epithelial cells are exposed to oxidative stress in vitro, their
GSH level initially drops, but later increases to levels higher than baseline (45). In
contrast with the enhanced glutathione levels in lining fluid of asthmatic reported by
Smith et al. (24), similar GSH and GSSG levels were found in induced sputum
samples of asthmatics and healthy subjects (46). As far as known, no data are
available on lung tissue levels of GSH and GSSG of asthmatics as compared to
healthy individuals. For a review on GSH regulation in inflammatory lung diseases,
including asthma, the reader is referred to (47).
Aim and outline of the present study
This thesis has addressed the relation between airway contractions and the
physiology of one of the most prominent airway antioxidants, GSH, as prompted by
accumulating evidence for an oxidative burden in asthmatic lungs, and by the fact
that excessive airway smooth muscle contraction is a hallmark of asthma.
In chapter 2, it was investigated whether contractile differences between isolated
proximal and distal trachea segments can be attributed to differential GSH content
or to differential production or release of contractile and relaxant mediators.
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The relaxing properties of GSH and other thiols in isolated and perfused guinea pig
trachea have been demonstrated in chapter 3, and the question has been addressed
which mediators of trachea tone are involved in GSH-induced tracheal relaxation.
Since the consequences of allergic inflammation and the associated oxidant burden
in the airways for lung GSH levels are unclear, the effects of an early asthmatic
response (EAR) in vivo on GSH concentrations in guinea pig lung tissue have been
studied in chapter 4. Using a setup for perfusion of isolated lungs, the protective
effect of exogenous GSH against excessive airway contractions during an EAR was
shown. The effects of experimental GSH depletion in guinea pigs on contractile
responsiveness to histamine of isolated and perfused lungs has been demonstrated in
the same chapter.
Chapter 5 describes the effects of a tissue GSH enhancing diet on lung contractions
during an EAR in a guinea pig model of allergic asthma. It was also investigated
whether this diet affected allergen-induced concentrations of various contractile and
relaxant mediators in the airways, as well as parameters of oxidative stress.
In chapter 6, a murine model of allergic asthma was used to address the possibility
of an intervention by delivering GSH-donors to the lungs via aerosols. The aerosols
consisted of GSH-ethyl ester or N-acetylcysteine and were delivered shortly before
or during respiratory allergen challenges, or during methacholine challenges. The
effect of these treatments on airway reactivity, as well as on lung GSH content, and
recruitment of inflammatory cells into the airways has been examined.
Finally, in chapter 7, the results of the experimental studies as a whole are discussed
in the context of related literature.
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Abstract
The present study addressed the question whether proximal and distal trachea
segments of the guinea pig respond differently to contractile agents.
Using a perfused trachea set-up, application of histamine at the luminal side of the
trachea induced similar contractions in proximal and distal trachea segments.
However, a pharmacologically non-specific contractile stimulus, serosal KCl (50
mM), induced a 60% stronger contraction in proximal trachea as compared to distal
trachea. Similarly, the increase of histamine-responsiveness as induced by removal
of the epithelium (a mimic for epithelial sloughing in asthmatics) was significantly
greater in proximal than in distal trachea segments (Emax values 3057 and 1526 mg,
respectively). In epithelium-intact tracheas, inhibition of epithelial nitric oxide
synthase increased histamine-induced contractions in proximal segments only, while
inhibition of mucosal cyclo-oxygenase increased reactivity to histamine to the same
degree in proximal and distal epithelium. In contrast, serosal cyclo-oxygenase
inhibition increased histamine-reactivity in proximal trachea segments only (Emax
2690 and 5180 mg without and with cyclo-oxygenase inhibitor, respectively). Levels
of glutathione, a compound that has moderating effects on airway contractions, were
similar in proximal and distal trachea segments. The results indicate that the higher
intrinsic contractility of proximal trachea segments is counteracted by epithelial
nitric oxide synthase and serosal cyclo-oxygenase.
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Introduction
One of the hallmarks of asthma is increased responsiveness of the airways to
contractile mediators such as histamine (1). Airway contractions are widely studied
in isolated parts of the airways. There is abundant evidence for contractile reactivity
differences between upper and lower airways, but such differences within the
tracheal tube are less well documented. However, in vitro experiments are often
performed on multiple pieces of tissue from the same trachea. Hence, for practical
reasons, it is important to know whether there are reactivity differences between
different parts of the trachea. In addition, investigation of possible differences may
shed new light on the relative role of factors defining tracheal responsiveness.
In our laboratory, an organ bath system with perfused isolated guinea pig tracheas is
used. To reduce the use of experimental animals, we generally separate each trachea
into a proximal and a distal part. Trachea segments without epithelium are
frequently used as a model to mimic epithelial sloughing (2) as seen in asthmatics
(3). Using this model with histamine as a contractile agent, we observed contractility
differences between proximal and distal parts of guinea pig tracheas. This was
further investigated by using tracheas with and without epithelium. Since the
contractility differences were especially pronounced in the absence of the
epithelium, the role of two histamine-induced, epithelium-derived relaxing factors,
nitric oxide (NO) (4) and prostaglandin E2 (PGE2) (5), was studied. Further, we
studied whether GSH is involved in the contractile differences, since GSH is
abundant in airway epithelium (6) and capable of counteracting airway contractile
responses (chapters 3, 4, 5, and 6).
Methods
Animals
Male specific pathogen-free Dunkin Hartley guinea pigs weighing 350 - 400 g
(Harlan Nederland, Horst, The Netherlands) were housed under controlled
conditions. Water and commercial chow were allowed ad libitum.
Isolation of tracheal segments
Guinea pigs were sacrificed with an overdose of pentobarbitone-sodium
(Nembutal, 0.6 g kg-1 body weight, i.p.). Tracheas were dissected free of
connective tissue and blood vessels, isolated, and divided in a proximal and distal
part as follows: the part of the trachea that contained the first 14±1 cartilage rings
from the larynx was designated proximal, and the part containing the following 14±1
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rings was designated distal parts of the trachea. Typically, 3 or 4 rings separated the
latter part from the bifurcation, but were not included because of practical reasons
relating to the isolation procedure. Two steel hooks were inserted through opposite
sites of the tracheal wall with the smooth muscle between them as described before
(2). The hooks comprised three cartilage rings; therefore, the sites of proximal and
distal parts where force development was actually recorded were separated by 11±2
cartilage rings. Where indicated, the epithelial layer was removed from the tracheal
segments by gently rubbing with a cotton swab as described earlier (2).
Perfused organ baths
Trachea segments were mounted in perfused organ baths according to a modified
method of Pavlovic (7). The organ baths contained Krebs buffer of the following
composition (mM): NaCl (118.1), KCl (4.7), CaCl2 (2.5), MgSO4 (1.2), NaHCO3
(25.0), K2HPO4 (1.2), glucose (8.3). The mucosal side of the trachea was perfused
with Krebs solution independently from the serosal side by means of a peristaltic
pump delivering a flow rate of 2 ml/min. The Krebs solution was continuously
gassed with 5% CO2 in O2 and kept at 37°C. One hook was fixed to the bottom of
the organ bath; the other hook was attached to an isometric force transducer
(Harvard Bioscience, Kent, UK). Transducers were connected to an analogue-digital
converter, delivering digital signals to a computerized set-up. The set-up allowed
continuous sampling, on-line equilibrium detection, and real-time display of the
responses on a computer screen.
The tracheal tension was set at an optimum counter weight of 2.0 g. The tissues were
allowed to reach a stable tone for 60 min, during which the buffer was refreshed
every 15 min. If necessary, tissues were allowed additional time to equilibrate
without the buffer solution being changed.
Contractile stimulation; pharmacological modulation of contractions
Non-specific trachea smooth muscle responses were evoked by adding KCl at a final
concentration of 50 mM to the serosal buffer. For pharmacologically specific
contractile responses, tracheas were stimulated at the mucosal side with
cumulatively increasing concentrations of histamine (10-8 to 10-3 M), or with a single
concentration (10-3 M) of histamine at the serosal side of the tracheal tube.
NO synthase (NOS) was inhibited by L-NAME (150 μM, final concentration),
which was administered after the equilibration period, but 20 min before starting the
histamine series. Tracheas with epithelium received the NOS-inhibitor in the
mucosal buffer only, whereas epithelium-denuded tracheas were treated both
serosally and mucosally. Controls received the same concentration of D-NAME; the
compounds remained in the buffer throughout the experiment. The cyclo-oxygenase
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inhibitor, indomethacin (1.0 μM, final concentration), was administered in a similar
fashion; controls received vehicle (Tris buffer, 2.5 mM, final concentration).
GSH/GSSG measurements
Tracheas were isolated from the animals, divided in a proximal and distal part as
described above, and snap frozen in liquid nitrogen. Three segments per sample
were crushed using a mortar and pestle; the resulting powder was divided between
two eppendorf tubes. In one tube, a mixture of 1 M HClO4 with 2 mM EDTA was
added (1 ml per 250 mg powder) to assay total glutathione (GSH + GSSG), while
the same mixture supplemented with 10 mM N-ethyl maleimide (NEM) was added
to the other tube to assess levels of oxidized glutathione. After vigorous vortex
mixing, tubes were centrifuged at 5000 g for 10 min and total and oxidized
glutathione concentrations in the supernatants were determined with a modified
version (8) of the glutathione reductase-DTNB recycling assay according to
Akerboom et al. (9). Values were expressed in nmole per g tissue (wet weight).
Statistics
If concentration response curves showed a clear plateau, Emax values were compared
with the Student’s two-tailed T-test. This test was also used to analyze the data on
tracheal GSH and GSSG content. If no clear plateau was reached, the curves were
analyzed with a repeated measures test. P-values < 0.05 were considered to reflect
significant differences.
Results and discussion
Mucosal perfusion with histamine of tracheas with intact epithelium resulted in
concentration-dependent increases of reactivity that were similar for proximal and
distal segments at all concentrations, except at the highest (1 mM) (figure 1). At the
latter concentration, stronger contractions were observed in proximal segments than
in distal ones.
Moreover, when intact tracheal tubes were stimulated non-specifically at the serosal
side with KCl (50 mM), proximal segments showed stronger contractions than distal
segments as well (figure 2). Apparently, the intrinsic contractile capacity of tracheal
smooth muscle is higher in proximal than in distal tissue. Combining the results of
figures 1 and 2, we hypothesized that in intact tracheal tissue, the epithelium of the
proximal trachea conceals the higher contractile potential of proximal segments. To
test this hypothesis, contractility of tracheal tubes without epithelium to histamine in
the mucosal buffer was assessed.
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Figure 1. Contractions of proximal (squares) and distal (triangles) guinea pig trachea
segments with intact epithelium following exposure to increasing histamine
concentrations administered at the mucosal side. Proximal and distal segments respond
differently to the highest concentration of histamine only. N = 9 trachea segments per
group.
Results showed that epithelium-denuded proximal tubes exhibited substantially
higher contractions than similar distal ones throughout the concentration range
(figure 3; Emax 3057 vs. 1526 mg; P < 0.0005).
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Figure 2. Contractions of proximal and distal guinea pig trachea segments with intact
epithelium upon stimulation with 50 mM KCl at the serosal side. Proximal segments
contract more than distal segments (*, P < 0.05). N = 9 trachea segments per group.
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Figure 3. Contractions of proximal (squares) and distal (triangles) guinea pig trachea
segments without epithelium following exposure to increasing histamine concentrations
at the mucosal side. Proximal segments are more responsive to histamine than distal
segments (*, P < 0.0005). N = 9 trachea segments per group.
The findings in figure 3 can not be entirely explained by the notion that the overall
stronger contractility of epithelium-denuded tracheas as compared to tracheas with
epithelium (figure 1) accentuates proximal-distal contractile differences. Notably, in
intact tracheas, contractions of proximal and distal segments are similar for
contractions up to 1000 mg (figure 1) whereas differences between proximal and
distal segments in epithelium-denuded tracheas are obvious even at contractions far
below 1000 mg (figure 3). Thus, assuming that epithelial permeability to histamine
is the same in proximal and distal segments, we concluded that a relaxing factor in
the epithelium of the proximal trachea compensates for the higher intrinsic smooth
muscle contractility in proximal trachea segments.
In the light of these considerations, the role of one of the major epithelium-derived
relaxing substances in the airways, NO (10, 11), was studied. It has been reported
that tracheal NO is produced by the epithelium (12) and is implicated in the
functional antagonism of histamine-induced airway contractions (4, 13, 14). If this
would be the case mainly in the proximal trachea, inhibiting epithelial NOS should
have a more pronounced effect in proximal than in distal trachea segments. The
NOS inhibitor, L-NAME, had no effect in distal segments but tended to increase the
response to histamine in the proximal segments throughout the concentration
response curve as compared to the inactive enantiomer D-NAME (figure 4).
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Figure 4. Effect of mucosal inhibition of NO-synthase in guinea pig trachea segments
with intact epithelium on contractile responses to mucosal histamine. The NO-synthase
inhibitor, L-NAME (dashed lines), tended to increase histamine-induced contractions in
proximal (squares), but not in distal (triangles), segments as compared to its inactive
enantiomer, D-NAME (solid lines). N = 6 trachea segments per group.
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Figure 5. Effect of concomitant mucosal and serosal inhibition of NO-synthase in
guinea pig trachea segments without epithelium on contractile responses to mucosal
histamine. The NO-synthase inhibitor, L-NAME (dashed lines), had no effect on
histamine-induced contractions in proximal (squares) or distal (triangles) segments as
compared to its inactive enantiomer, D-NAME (solid lines). N = 6 trachea segments per
group.
Since NOS inhibition was without any effect in epithelium-denuded tissues (figure
5), a substantial part of the reactivity differences in epithelium-denuded tracheas is
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accounted for by a lack of epithelial NO. However, NO could not completely
account for the relaxant activity in proximal segments. Therefore, the contribution of
cyclo-oxygenase metabolites to the relaxant activity was studied as well. Like NO,
prostaglandins have been shown to counteract histamine-induced contractions in the
airways (5, 15). In intact tracheas, cyclo-oxygenase inhibition by indomethacin in
the mucosal buffer increased reactivity to histamine in proximal and distal segments
to a similar extent (figure 6).
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Figure 6. Effect of mucosal cyclo-oxygenase inhibition on contractile responses of
guinea pig trachea segments with intact epithelium. Contractions were induced by
histamine at the mucosal side. The cyclo-oxygenase inhibitor, indomethacin (dashed
lines), increased histamine-induced contractions both in proximal (squares) and in
distal segments (triangles) as compared to its vehicle (solid lines). (*, P < 0.05) N = 6
trachea segments per group.
This indicates that, contrary to the findings for NO, relaxing cyclo-oxygenase
metabolites are synthesized in both proximal and distal trachea segments. Since
indomethacin increased tracheal tension when given mucosally, the epithelium is the
most likely source of cyclo-oxygenase metabolites in these experiments.
Quite surprisingly, however, indomethacin administered concomitantly at the
mucosal and serosal side of epithelium-denuded tracheas led to a marked increase of
histamine-induced contractions in proximal, but not in distal, segments as compared
to controls (figure 7). The data suggest that in proximal trachea segments, apart from
the contributions of epithelium-derived NO, one or more non-epithelial cyclo-
oxygenase metabolites clearly compensate for the higher intrinsic smooth muscle
reactivity in these segments. This notion was confirmed by the observation that in
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proximal segments with intact epithelium, histamine induced stronger contractions
when indomethacin was present both in the mucosal and the serosal buffer than
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Figure 7. Effect of concomitant serosal and mucosal cyclo-oxygenase inhibition with
indomethacin on contractile responses of guinea pig trachea segments without epithelium.
Contractions were induced by histamine at the mucosal side. Indomethacin had no effect
on histamine-induced contractions in distal segments (dashed line, triangles) compared to
its vehicle (solid line, triangles). In contrast, indomethacin substantially increased
responsiveness to histamine of proximal segments (dashed line, squares) as compared to
vehicle treatment (solid line, squares). (*, P < 0.05) N = 6 trachea segments per group.
when indomethacin was administered in the mucosal buffer only (figure 8).
Moreover, serosal stimulation with histamine led to an additional increase in tension
when mucosal and serosal cyclo-oxygenase was inhibited, but to a decrease in
tension when the cyclo-oxygenase inhibitor was only present in the mucosal buffer
(figure 8). Thus, in the proximal trachea, cyclo-oxygenase inhibition in serosal
tissues has a larger effect on smooth muscle contraction than cyclo-oxygenase
inhibition in mucosal tissues. In contrast, inhibition of cyclo-oxygenase in serosal
tissues of the distal trachea had no additional effect on smooth muscle reactivity
compared to cyclo-oxygenase inhibition in mucosal tissue only (figure 7). Therefore,
we conclude that cyclo-oxygenase products from the serosa of the proximal trachea
have a dampening effect on trachea smooth muscle reactivity of this segment. This
finding may be very relevant. Since histamine induces the production of cyclo-
oxygenase products (5, 15) and since histamine is mainly produced by mast cells
that inhabit the serosa, serosal cyclo-oxygenase products may be important
functional antagonists of allergen-induced contractions in proximal trachea
segments.
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Figure 8. Comparison of the effects of mucosal cyclo-oxygenase inhibition with
concomitant mucosal and serosal cyclo-oxygenase inhibition in proximal trachea
segments with intact epithelium. Mucosal histamine induced stronger contractions when
the cyclo-oxygenase inhibitor, indomethacin, was present both in the mucosal and the
serosal buffer (squares) than when indomethacin was administered in the mucosal
buffer only (circles). Histamine given serosally (out) after the mucosal doses led to a
decrease in tension in the absence of a cyclo-oxygenase inhibitor in the serosal buffer,
but to an additional increase in tension when a cyclo-oxygenase inhibitor was present in
the serosal buffer. (*, P < 0.05 (with vs. without serosal cyclo-oxygenase inhibitor)) N =
9 trachea segments per group.
A substance of which we recently showed that it could moderate airway tension
(chapters 3, 4, 5, 6) is GSH. Since levels of both GSH and its oxidized form, GSSG,
were similar in proximal and distal trachea segments (Table 1), it is excluded that
the differential reactivity can be accounted for by different levels in proximal and
distal trachea of this thiol.
proximal distal
GSH 485 ± 22.3 465 ± 49.4
GSSG 6.5 ± 3.7 10.1 ± 5.4
Table 1. GSH and GSSG content (nmol/g wet tissue) of proximal and distal trachea
segments are not significantly different. Figures represent the mean ± SEM of three
samples, each containing 3 segments.
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The introduction of the perfused trachea organ bath system made it possible to study
the consequences of selective stimulation of the mucosal or serosal tissues. Such
studies have identified the tracheal epithelium as a source of relaxing factors (see
(16) for a review). However, to our knowledge, this is the first study to demonstrate
that the serosa has a distinct role in the modulation of tracheal tone as well and that
this is particularly true for the proximal part of the trachea. Further research is
needed to identify which cyclo-oxygenase products counteract contraction and
which cells produce the cyclo-oxygenase products in the serosa. In addition to the
epithelium, constitutive cyclo-oxygenase expression has been demonstrated in
cultured human airway fibroblasts and smooth muscle cells (17).
Another question that remains to be answered is whether hyperreactivity induced by
cyclo-oxygenase inhibition is indeed merely the result of downregulating the
synthesis of cyclo-oxygenase products. Since cyclo-oxygenase and lipoxygenase
compete for arachidonic acid, cyclo-oxygenase inhibition may increase the synthesis
of lipoxygenase products (18). This may provide an alternative mechanism for
indomethacin-induced hyperreactivity in these experiments. To test this, experiments
in the presence of leukotriene receptor antagonists, or the combined presence of
cyclo-oxygenase and lipoxygenase inhibitors, should be done.
We conclude that in the guinea pig, intrinsic contractility of tracheal smooth muscle
tissue is higher in the proximal than in the distal segment. This higher contractility is
clearly compensated for both by mucosal NO and serosal cyclo-oxygenase products.
Neglecting these differences can easily lead to larger variances when studying
multiple pieces of one trachea. This may lead to the use of more, rather than less
experimental animals in order to attain statistically significant results. In addition,
false conclusions may be drawn regarding intrinsic smooth muscle contractility, or
the importance of NOS or cyclo-oxygenase in the trachea. Conceivably, similar
complications may apply to other pathways as well. Thus, it is important to perform
pilot experiments to investigate whether there are differences within the trachea
regarding the effects on tracheal tone of the particular pathway under study.
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Abstract
The aim of this study was to determine the effects of glutathione (GSH) on trachea
smooth muscle tension in view of previously reported interactions between GSH
and nitric oxide (NO), and the high (millimolar) concentrations of GSH in trachea
epithelium.
GSH and other thiols (1.0 – 10 mM) dose-dependently decreased the tension in
isolated epithelium-denuded guinea pig tracheas, and less so in intact tracheas.
Relaxations by GSH were paralleled by a 7-fold increase in nitrite levels (P < 0.05)
in the tracheal effluent, suggesting an interaction between GSH and NO. However,
preincubation with the NO scavenger, PTIO (100 μM), did not reduce the
relaxations by GSH or its NO-adduct, S-nitrosoglutathione (GSNO).
Inhibition of guanylyl cyclase with ODQ (50 μM) inhibited the relaxations induced
by GSNO, but not by GSH. Blocking potassium channels with tetraethylammonium
(20 mM), however, completely abolished the relaxing effects of GSH (P < 0.05).
Preincubation of tracheas with GSH significantly (P < 0.05) suppressed
hyperreactivity to histamine as caused by removal of tracheal epithelium. In
contrast, GSH did not significantly affect histamine-induced contractions in intact
tracheas. These data indicate that GSH plays a role in maintaining tracheal tone. The
mechanism behind this is possibly an anti-oxidative action of GSH itself, rather than
an action of NO or GSNO.
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Introduction
Airway hyperresponsiveness is a key feature of several lung diseases. It is often
associated with epithelial damage as a consequence of inflammatory processes (1).
Damaged epithelium is impeded in its role of protecting the underlying smooth
muscle against contractile stimuli. Moreover, the function of the epithelium as a
source for relaxing factors that compensate for contractile stimuli will be impaired
(2). One of those endogenous airway smooth muscle relaxants is nitric oxide (NO).
NO is produced by a variety of cells and tissues in the respiratory tract, including
the epithelial layer (3, 4). Under physiological conditions, genuine NO is very
unstable and rapidly loses its biological activity by reacting almost instantaneously
with oxygen, superoxide anion and transition metals (5-7). Maintenance of an
appropriate smooth muscle tone in the airways, therefore, requires continuous
synthesis as well as stabilization of NO. Thiols are excellent candidates for the latter
purpose. Under aerobic conditions, NO reacts with thiols to form nitrosothiols
(RSNOs) via the nitrosylating intermediate dinitrogen trioxide (8). RSNOs are also
produced by direct binding of nitrosonium ions to thiols (9). RSNOs can be
regarded as stable pools of NO (10). Whereas in principle any thiol can bind NO,
glutathione (GSH) is probably especially important in this respect. GSH is the major
representative of the class of non-protein thiols and plays a pivotal role in a variety
of enzymatic and non-enzymatic reactions that protect tissues against oxidative
stress (11). In view of the anti-oxidant role of GSH and wide spread interactions
between oxygen and tissues in the airways, it is not surprising that the airways are
among the tissues containing the highest GSH concentrations in the body.
Especially lung epithelial cells (12) and the epithelial lining fluid in the lungs
contain high levels of GSH (13).
In anti-oxidative reactions, GSH is converted into its oxidized form, glutathione
disulfide (GSSG), that in its turn is enzymatically reduced into GSH to maintain a
physiological redox balance. Under normal conditions, 95 – 99% of total glutathione
in the body is present in the reduced form (11). However, inflammatory diseases
like asthma are associated with oxidative stress that places a large burden on the
GSH pool. This may result in decreased levels of GSH available for NO
stabilization and thus contribute to the development of airway hyperresponsiveness.
Indeed, evidence was recently presented that an oxidative imbalance in the airways
of asthmatics is reflected, among other parameters, by high levels of GSSG (14).
To address these issues, we tested whether addition of GSH to epithelium-denuded
guinea pig tracheas increased NO levels as judged by a rise of nitrite levels in the
perfusion buffer and, if so, whether the increased nitrite levels showed a causal
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correlation with relaxation of tracheal smooth muscle. Since GSH-induced
relaxations were indeed paralleled by a rise in nitrite levels in the buffer, it was
investigated whether these relaxations were mediated by guanylyl cyclase or by
potassium channels, both of which are known play a role in NO-induced smooth
muscle relaxation. Finally, the physiologic relevance of alteration of tracheal tension
by GSH was assessed by measuring whether perfusion of tracheas with GSH could
moderate the hyperresponsiveness resulting from removal of their epithelium.
Methods
Animals and organ bath experiments
Male specific pathogen-free Dunkin Hartley guinea pigs weighing 350 - 400 g
(Harlan Nederland, Horst, The Netherlands) were housed under controlled
conditions. Water and commercial chow were allowed ad libitum. Guinea pigs were
killed with an overdose of pentobarbitone-sodium (Nembutal, 0.6 g/kg body
weight, i.p.). Tracheas were dissected free of connective tissue and blood vessels,
isolated, and divided into a proximal and distal part. Where indicated, the epithelial
layer was removed from the tracheal segments as described earlier (15). Tracheas
were mounted in perfused organ baths according to a modified method of (16). The
organ baths contained Krebs buffer of the following composition (mM): NaCl
(118.1), KCl (4.7), CaCl2 (2.5), MgSO4 (1.2), NaHCO3 (25.0), K2HPO4 (1.2),
glucose (8.3). The lumen of the trachea was perfused with Krebs solution
independently from the outside by means of a peristaltic pump delivering a flow rate
of 2 ml/min. The Krebs solution was continuously gassed with 5% CO2 in O2 and
kept at 37°C. Two steel hooks were inserted through opposite sites of the tracheal
wall with the smooth muscle between them. The lower hook was fixed to the bottom
of the organ bath; the other hook was attached to an isometric force transducer
(Harvard Bioscience, Kent, UK). Transducers were connected to an analogue-digital
converter, delivering digital signals to a computerized set-up. The setup allowed
continuous sampling, on-line equilibrium detection and real-time display of the
responses on a computer screen.
The tracheal tension was set at an optimum counter weight of 4.0 or 2.0 g for thiol-
induced relaxations and histamine-induced contractions, respectively. The use of
different pretensions for assessing effects of relaxing and contractile agents is
common practice in organ bath studies. The tissues were allowed to reach a stable
tone for 60 min, during which the buffer was refreshed every 15 min. If necessary,
tissues were allowed additional time to equilibrate without the buffer solution being
changed.
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Thiol-induced tracheal relaxation
Epithelium-denuded tracheas were consecutively perfused with a range of
concentrations (0.1 to 10 mM) of GSH, L-cysteine (Cys) or N-acetyl-L-cysteine
(NAC). As a control, the non-thiol amino acid L-valine was tested at the same
concentrations. In a separate set of experiments, GSH-induced relaxations were
recorded in epithelium-denuded and in intact tracheal tubes, using the same range of
concentrations as mentioned above.
Mechanisms of GSH-induced tracheal relaxations
Interactions with NO
For NO measurements, nitrite was assayed as a stable and representative breakdown
product of NO formed enzymatically or NO released from nitrosothiols (9). Samples
of 100 µl tracheal effluent were collected just prior to or immediately after addition
of GSH. The samples were injected into a purge vessel containing 2 ml of a 1%
solution of sodium iodide in glacial acetic acid. The purge vessel was connected to a
Sievers 270B NO analyzer (Boulder, CO, USA). The sensitivity of the NO analyzer
is 10 pmol/ml with a linearity of four log orders of magnitude. Calibrations were
made according to the manufacturer’s instructions with standard solutions of sodium
nitrite (17).
In a separate set of experiments, the potential role of free NO in GSH-induced
relaxations was investigated using the NO scavenger, 2-phenyl-4,4,5,5-
tetramethylimidazoline-1-oxyl-3-oxide (PTIO) (18). PTIO was added to the luminal
buffer after the 60-minute-equilibrium period at a final concentration of 100 µM.
Twenty min after adding PTIO, tracheas were relaxed by intraluminal addition of
GSH, GSNO or GTN. The compounds were given in concentrations that evoke a
sub-maximal response, i.e. 5.0 mM, 100 µM and 10 µM for GSH, GSNO and GTN,
respectively. PTIO remained in the buffer during the relaxations.
The inhibitor of soluble guanylyl cyclase (sGC), 1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one (ODQ) (50 µM) (19), or the non-selective potassium (K+-)
channel blocker, tetraethylammonium (TEA) (20 mM) (20), were applied both to
the mucosal and the serosal buffer. Controls received the vehicle of ODQ (DMSO;
0.25% (v/v) final concentration). After 20 min of incubation, GSH (5 mM) or S-
nitrosoglutathione (GSNO, 100 µM) was added to the luminal buffer without
removing TEA or ODQ and relaxations were recorded.
Interactions with PGE2
A 100 μl sample of the luminal perfusate of tracheas was taken before and after the
addition of GSH to be assayed for PGE2 content. PGE2 was quantified with an
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enzyme-linked immunoassay (Amersham, Roosendaal, The Netherlands) according
to manufacturer’s instructions.
Effect of GSH on tracheal responsiveness to histamine
Epithelium-denuded tracheas were pre-incubated intraluminally with GSH at a
concentration of 1.0 mM, or saline (controls). After 40 min, optimum tension (2.0 g)
was re-adjusted mechanically and contractions were measured to increasing
concentrations (10-8 to 10-3 M) of histamine in the inside buffer. GSH or saline were
left in the buffer during histamine-induced contractions.
Drugs
GSH, NAC, Cys and L-valine were obtained from Sigma, St. Louis, MO. ODQ,
GSNO and PTIO were purchased from Alexis, Lausen, Switzerland and TEA from
Merck, Darmstadt, Germany. Glyceryl trinitrate (GTN) was obtained from
Brocacef, Maarssen, The Netherlands.
Data analysis
Relaxations were determined as the percentage of the 4.0 g baseline tone that was
set after completion of the equilibration period. Contractions were expressed as mg
tension on top of the 2.0 g baseline tone. Data are expressed as mean ± SEM. For
most experiments, significance calculations were performed using the two-tailed
Student’s t-test. However, the Wilcoxon signed-rank test was used for assessing the
statistics of the nitrite measurements, while a repeated measures analysis with
L.S.D. post hoc test was used for analysis of the data pertaining to histamine
reactivity. Differences were considered statistically significant if P < 0.05.
Results
Thiol-induced tracheal relaxation
GSH, as well as the sulfhydryl amino acids, Cys and NAC, relaxed tracheas without
epithelium dose-dependently at concentrations of 1.0 mM and higher (figure 1A).
Relaxations started within seconds after administration of thiols (figure 2 shows a
representative tracing of a relaxant response to GSH; the profile of the relaxations
was similar for all thiols). The sensitivity to the tested compounds increased in the
order Cys << GSH < NAC. When administered at the highest concentration (10
mM), Cys, GSH and NAC reduced the initial 4.0 g baseline tension by about 20, 65
and 70%, respectively. As expected, L-valine, which does not have a thiol group,
did not significantly alter baseline tension at any concentration (data not shown).
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GSH-induced relaxations were more extensive in denuded tissues than in tissues
with intact epithelium (figure 1B). At 10 mM, GSH reduced the initial 4.0 g baseline
tension by 65.7 ± 6.5% in denuded tracheas and by 36.7 ± 5.9% in intact tracheal
tubes.
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Figure 1. Relaxing effects of the thiol compounds, GSH (squares), NAC (triangles)
and Cys (circles) in guinea pig tracheas without epithelium (A) and the inhibitory
influence of the epithelium on the relaxing effects of GSH (B; solid line, intact
trachea; dashed line, denuded trachea). Change of tension is expressed as the
percentage of a 4.0 g baseline tone. * P < 0.05; N = 9 in each group.
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Figure 2. Representative tracing of the relaxation of an epithelium-denuded tracheal
tube as induced by increasing concentrations of GSH in the luminal buffer. Arrows
indicate time of administration; the respective GSH concentrations (log molar) are
indicated.
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Mechanisms of GSH-induced tracheal relaxations
Since NO is a well-known smooth muscle relaxant that can interact with thiols, we
measured whether perfusion with GSH increased nitrite levels in the tracheal
effluent.
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Figure 3. Effect of addition of GSH on nitrite concentrations in the luminal buffer.
Samples were taken just before (control) and immediately after addition of GSH (10
mM, final concentration) to the perfusing buffer. * P < 0.05; N = 6 in each group.
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Figure 4. Effect of scavenging free NO by PTIO (100 μM), on relaxations induced by
GSH, GSNO or GTN in isolated perfused guinea pig trachea. White bars, control;
black bars, PTIO. Change of tension is expressed as the percentage of a 4.0 g baseline
tone. ** P < 0.01; N = 6 in each group.
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After the 60-minute-stabilization period, i.e. just before addition of GSH, nitrite
levels in the tracheal effluent were 0.9 (95% confidence interval, 0.62 – 1.2) µM,
whereas immediately after addition of 10 mM GSH, levels increased significantly (P
< 0.05) to 7.9 (95% confidence interval 4.3 – 11.4) µM (figure 3), suggesting
release of NO from the tissue by GSH.
To further address a possible role for NO in GSH-induced relaxations, the NO-
scavenger, PTIO (18), was added to the perfusion buffer prior to administration of
GSH, GSNO or GTN. PTIO did not significantly alter GSH- or GSNO-induced
relaxations (figure 4). Since PTIO, in contrast, significantly decreased relaxations by
the genuine NO donor, GTN, it is unlikely that the GSH- and GSNO-induced
relaxations were mediated through free extracellular NO. Furthermore, it was
investigated whether a major target of NO and GSNO, guanylyl cyclase, was
involved in the relaxations evoked by GSH. Preincubation with the sGC inhibitor,
ODQ (21), did not affect the ability of GSH to cause tracheal relaxation (figure 5),
suggesting that the relaxing effect of GSH was not due to a rise in cGMP levels.
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Figure 5. Effects of inhibition of sGC (ODQ, 50 μM) or K+-channels (TEA, 20 mM)
on GSH-induced (5 mM) relaxation of isolated and perfused guinea pig tracheas. For
comparison, another set of tracheas received GSNO instead of GSH. White bars,
control; black bars, ODQ; hatched bars, TEA. Change of tension is expressed as the
percentage of a 4.0 g baseline tone.
* P < 0.05, ** P < 0.01; N = 6 in each group.
An alternative target in smooth muscle relaxation by NO are K+-channels. Upon
treatment with the non-specific K+-channel inhibitor TEA (20), the GSH-induced
relaxations were almost completely abolished (figure 5), suggesting that K+-
channels mediate thiol-induced relaxations. Further, it was investigated whether
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GSNO, a potential product of interaction of GSH and NO, mediates GSH-induced
relaxations. To this end, the experiments with ODQ and TEA were carried out with
GSNO as the relaxing agent. In these experiments, relaxations were inhibited both
by ODQ and, to a lesser extent, TEA (figure 5).
Interactions with PGE2
Levels of PGE2 in the luminal perfusate were 134 ± 18 pg/ml under baseline
conditions. Upon addition of GSH, PGE2 levels in the perfusate remained
unchanged (124 ± 57 pg/ml; N = 6).
Effect of GSH on tracheal responsiveness to histamine
Perfusion of intact tracheas with histamine caused a moderate concentration-
dependent increase of smooth muscle tension, whereas contraction after removal of
epithelium started at lower concentrations of histamine and was markedly stronger.
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Figure 6. Effect of GSH on histamine-induced contractions in isolated perfused
tracheas. Intact and epithelium-denuded tracheas were exposed to GSH (1.0 mM)
before and during histamine-induced contractions. Squares, control; triangles, GSH;
solid lines, intact trachea; dashed lines, denuded trachea. * P < 0.05; N = 9 per group.
This hyperresponsiveness upon removal of epithelium has been reported earlier (22,
23). Preincubation with 1.0 mM GSH significantly attenuated the hyperreactivity in
tracheas without epithelium by 31.6 ± 9.46 % in terms of maximum response to
histamine, but did not change responsiveness of tracheas with intact epithelium
(figure 6).
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Discussion
In this study, we have shown that GSH and other thiols reduced the smooth muscle
tone of epithelium-denuded guinea pig tracheas in perfused organ baths. Relaxations
up to 65 to 70% below baseline tension were induced by 10 mM GSH or NAC, the
highest concentration tested (figure 1A). This concentration may be physiologically
relevant since GSH is estimated to be present at this concentration in epithelial cells
(12). Relaxations induced by Cys appeared less pronounced. Whether this indicates
that the thiols need to be taken up in target cells to exert their relaxing effect is not
clear. NAC, but not Cys, diffuses readily across the cell membrane. Uptake of GSH,
however, has been shown to require an active transport mechanism that is present in
epithelial cells, but absent in many other cell types tested (24-26). In addition, the
almost instantaneous relaxation induced by the thiols points to an extracellular
rather than an intracellular mechanism. L-valine failed to relax tracheas at any
concentration, suggesting that induction of relaxation requires a sulfhydryl group
and was not due to non-specific effects such as osmolarity changes in the perfusion
buffer. GSSG may be better than L-valine to control for these properties, but we
obtained inconsistent results with GSSG. The compound had no effect on most
tracheas tested (N = 6), but it relaxed some tracheas (N = 3) to the same extent as
GSH. The latter observation is hard to explain. Since relatively high concentrations
were required for relaxation, instantaneous reduction of GSSG to GSH by the latter
tracheas seems unlikely.
Relaxations were more pronounced in epithelium-denuded tracheas, than in intact
tissues (figure 1B). The epithelium, therefore, possibly forms a physical barrier
against relaxation by GSH on the underlying smooth muscle. Alternatively, intact
epithelium already reduces tracheal tension by supplying the smooth muscle layer
with GSH, so that additional GSH can only have a limited effect.
Interestingly, GSH-induced relaxations in epithelium-denuded tissues were
paralleled by a seven-fold rise in nitrite levels in the tracheal effluent (figure 3),
suggesting release of NO by GSH (9). In view of the absence of the epithelium, the
increase of nitrite levels has to be derived from other sources than the NO-rich
epithelial cells. Sensory nerve endings in the trachea might have provided the NO
and thus be the putative source of nitrite (27). It is doubtful, however, whether GSH
caused relaxation by releasing genuine NO, in view of the effect of the free NO
scavenger, PTIO (18). This agent failed to inhibit relaxation by GSH while it clearly
inhibited relaxation by the genuine NO donor, GTN (28) (figure 4). So, free NO,
whether or not produced by nerve endings in the epithelium-denuded tracheas, is an
unlikely mediator of the GSH-induced relaxation and nitrite formation.
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 Alternatively, the GSH effects may involve nitrosylated proteins and other
molecules in the sub-epithelial tissues. Those are likely to have been formed there
prior to removal of the epithelium, because NO once produced can diffuse to
neighboring cells and nitrosylate protein and non-protein thiols via nitrosylating
agents, like dinitrogen trioxide (8) and nitrosonium ions (9). GSH would then
interact with tissue RSNOs to yield nitrite without the appearance of NO as an
intermediate (29). It is also known that GSH forms GSNO in the presence of protein
RSNOs (30). Although GSNO can cause tracheal relaxation, this molecule is also
unlikely to be the mediator of the GSH-induced relaxations, since inhibition by
ODQ of sGC, the primary target of NO and RSNOs (19), abolished the relaxing
effect of exogenous GSNO, but not of GSH.
To check whether PGE2 could mediate the GSH-induced relaxations, this major
relaxant prostanoid was measured in the perfusate of epithelium-denuded tracheas
before and during the GSH-induced relaxation. PGE2 levels remained unaltered
upon addition of GSH to the organ bath buffer. These data show that PGE2 is not
mediating GSH-induced relaxation.
In a further attempt to find a target of GSH that mediated the relaxations, the effects
of the non-specific K+-channel inhibitor TEA were investigated. TEA almost
completely abolished trachea relaxation by GSH (figure 5), suggesting that GSH can
activate particular K+-channels in this tissue. It is not unlikely that this is due to
modification of sulfhydryl groups, since sulfhydryl reagents and other oxidizing
compounds were reported to inactivate various K+-channels, while sulfhydryl
reducing agents, like dithiothreitol and GSH, were shown to reverse inactivation or
to cause their activation (31, 32). Further studies are needed identify which K+-
channel is involved in the observed relaxation and whether activation of that channel
is regulated by sulfhydryl modification.
Interestingly, K+-channel inhibition also inhibited GSNO-induced trachea
relaxation. Hence, in guinea pig trachea, GSNO apparently induces relaxation
through cGMP-induced K+-channel activation. cGMP-dependent activation of
calcium-activated K+-channels by nitrosothiols has been reported earlier in rabbit
coronary artery smooth muscle (33).
GSH not only caused trachea relaxation, but also counteracted histamine-induced
contraction in epithelium-denuded, but not intact, tracheas (figure 6). The more
pronounced activity in epithelium-free tracheas is probably due to the same
mechanisms as pointed out above. The finding, however, is relevant since airway
hyperresponsiveness is associated with sloughing of the epithelial layer (1).
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Smooth muscle cell relaxation by GSH and other reduced thiols may represent a
novel mechanism to maintain tracheal tone. Interestingly, this mechanism is
probably not mediated by NO or GSNO, but possibly by an anti-oxidative action of
GSH and other thiol compounds in the airways. Furthermore, the capacity of GSH
to attenuate hyperreactivity in a model for damaged epithelium such as occurs in
asthma (Figure 6) indicates that replenishment of GSH in the airways may have
therapeutic potential at physiological concentrations. Thiol replenishment in asthma
has only been described once. Nebulization of GSH in mild asthmatics caused
bronchoconstriction rather than a relief of symptoms (34), but this adverse effect
may have been caused by the supra-physiological concentration of GSH (0.5 M),
which was 500 times higher than the concentrations we used to dampen histamine-
induced contractions. In a proper dose, replenishing the sulfhydryl content in the
airways could be a potential therapy in diseases where excessive
bronchoconstriction and oxidative stress are concomitant features.
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Abstract
Substantial evidence suggests that oxidative stress in the lungs can affect the
pathological events observed in asthma. We used a guinea pig model of asthma to
assess whether the early asthmatic reaction is associated with decreased lung levels
of glutathione, and whether a decrease in glutathione is implicated in the increased
airway smooth muscle reactivity that is associated with exposure of the lungs to
allergen. Lung glutathione levels were decreased immediately after the onset of the
early asthmatic reaction in vivo. Glutathione-ethyl ester, a glutathione precursor,
blunted the airway obstruction during an early asthmatic reaction in a perfusion
model and glutathione depletion rendered the airways hyperreactive. Glutathione
ethyl ester in the buffer prevented this hyperreactivity. These results indicate that
glutathione modulates airway responsiveness in the early asthmatic reaction.
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Introduction
There is growing evidence that oxidant stress plays an important role in the
pathogenesis of asthma (1, 2) and COPD (3). It results in tissue damage, promotes
inflammation and shifts redox balances towards oxidative reactions (4-6).
The antioxidant, glutathione (GSH) is present in 15 mM concentrations in cultured
human lung epithelial cells (7) which is considerably higher than the concentrations
reported for most other cells (8). GSH concentrations in lung epithelial lining fluid in
vivo are approximately 450 µM; this is 100-fold higher than in plasma (9).
As an antioxidant, GSH is converted into its homodimeric disulfide, oxidized
glutathione (GSSG) (8). Increased formation of reactive oxygen species, resulting
from inflammation, enhances formation of GSSG and decreases the tissue content of
GSH (10). Although decreased GSH levels have been found in broncho-alveolar
lavage (BAL) fluid in several lung diseases (11), the BAL fluid from stable
asthmatics contains higher total glutathione levels than normal subjects (12). This
increase is thought to reflect an adaptive response to the oxidant stress of
inflammation (13).
GSH is known to influence rabbit and rat vascular (14, 15) and pig gastric (16)
smooth muscle relaxation. We recently found in the guinea pig trachea that the
hyperresponsiveness to histamine caused by removal of the epithelium is decreased
by adding GSH to the organ bath (chapter 3). To follow up on these findings, we
tested the hypothesis that an early asthmatic reaction (EAR) is associated with
decreased levels of GSH, and that the decreased GSH is implicated in the
development of airway hyperresponsiveness. To test this hypothesis, it was first
investigated whether an EAR as provoked by allergen in sensitized guinea pigs
decreased GSH levels in the lungs. Secondly, the effect on airway contractions of
supplementing GSH during an EAR was determined. Thirdly, airway reactivity to
histamine was measured in lungs of guinea pigs in which glutathione had been
depleted by pretreatment with a GSH synthesis inhibitor.
Methods
Ovalbumin sensitization
Male specific pathogen-free guinea pigs (Dunkin Hartley, Harlan Nederland, Horst,
The Netherlands) weighing 200 – 250 g body weight were sensitized by injecting a
mixture of 20 μg OVA (grade V, Sigma, St Louis, MO) and 200 mg of the adjuvant,
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Al(OH)3 (Merck, Darmstadt, Germany), in 1.0 ml saline. Al(OH)3 in saline was used
for the controls. Each animal received six injections: 0.5 ml was injected
intraperitoneally, and five injections (0.1 ml each) were made subcutaneously in the
axillar and inguinal regions and in the nuchal area. Three weeks after sensitization,
airways were challenged with OVA according to different challenge protocols as
described in the appropriate sections below.
Effect of an early asthmatic response on glutathione levels in the lungs
OVA- and sham-sensitized animals were placed individually in a plexiglas box and
exposed to a nebulized solution of OVA (0.01% in saline) until visual signs of an
EAR (breathing with difficulty, legs lifting the body higher than normal, eyes turning
darker) became apparent (typically after approximately one minute of OVA
exposure). At that time point, animals were given an overdose of pentobarbital
sodium (1 g/kg body weight, intraperitoneally) and were sacrificed within two
minutes. Lungs were isolated immediately and snap frozen in liquid nitrogen until
analysis for GSH/GSSG.
GSH depletion in vivo
Male Hartley strain guinea pigs (200 - 220 g, Charles River Laboratories,
Massachusetts) were depleted of GSH using D,R-buthionine-L-sulfoximine (BSO,
Sigma, St Louis), an inhibitor of γ-glutamylcysteine synthetase, the rate limiting
enzyme in GSH biosynthesis (17). BSO was dissolved in PBS and 2.5 mmol/kg body
weight was administered subcutaneously twice daily on four consecutive days.
Controls received PBS only. As opposed to controls, BSO-treated animals did not
gain weight in the course of treatment, but apart from that, appeared normal. On day
5, the lungs were isolated for perfusion studies.
Tracheally perfused lung preparation
Tracheal perfusion was performed as previously described (18). Guinea pigs were
anesthetized by intraperitoneal injection of 10% (w/v) urethane (2 ml/100 g body
weight). When a sufficient level of anesthesia was achieved, a 2-cm-long
polyethylene tube (1.67 mm I.D., 2.42 mm O.D.) was inserted into the trachea, the
abdominal cavity opened, 500 U of heparin injected into the vena cava, and 3 min
later the abdominal aorta was severed. The thoracic cavity was opened to remove
heart and lungs en bloc. The lungs were dissected free and hung in a plexiglas box at
37ºC, 100% relative humidity. The lungs were perfused via the tracheal cannula with
a phosphate-buffered physiological solution (pH 7.4) of the following composition:
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NaCl 137 mM, CaCl2 1.8 mM, MgCl2 1.05 mM, KCl 2.68 mM, NaHCO3 0.6 mM,
NaH2PO4 0.13 mM, and Na2HPO4 0.896 mM. The buffer was warmed to 45ºC and
pumped at a rate of 2 ml/min through a bubble trap before being cooled to 37ºC for
the actual lung perfusion. When the lungs had fully expanded, the buffer was
allowed to exit the lungs through multiple small holes made in the pleura. The “back
pressure” resulting from the perfusion (airway opening pressure, Pao) was recorded
from a side tap at the tracheal cannula with the use of a pressure transducer. We have
previously shown that during continuous flow, the Pao reflects the contractile state
of the lung (18). Subsequently, lungs were perfused for 10 min to give a stable
baseline pressure. At that time, different compounds were added to the buffer to test
their effect on airway resistance as described hereafter.
Figure 1. Representative tracings of the airway opening pressure (Pao) during an
allergen-induced early asthmatic reaction (EAR). Lungs from sham- (a) or OVA- (b)
sensitized guinea pigs were challenged ex vivo with OVA in the perfusion buffer. The
EAR-induced contraction of the lungs increased the Pao, while OVA challenge of a
control lung hardly evoked any response. 1. Decrease in Pao caused by punching
holes in the pleura; 2. The addition of OVA in the perfusion system results in a small
temporary increase in Pao, which, in OVA-sensitized animals, is followed by airway
contraction.
For the induction of an EAR, 3.0 mg OVA in 0.30 ml perfusion buffer was injected
in the perfusion system. Lungs contracted almost instantaneously upon the allergen
injection as shown in a representative tracing (figure 1). To control for allergen
specificity of the EAR, a few lungs were challenged with bovine serum albumin
followed by OVA.
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As a measure of the airway response, the area under the Pao curve from the OVA
infusion to the time of maximum resistance was recorded; values are expressed in
kPa x s.
To study contractility of GSH-depleted lungs, increasing doses of histamine (10-9 -
10-5 mole per dose) were added to the buffer. Because it was considered less
important to express these responses as a function of time, they were expressed in
kPa.
In some of the experiments described above, the cell-permeable GSH analogue
GSH-ethyl ester (GSEt; Sigma, St Louis, MO; 1.0 mM) was dissolved in the
perfusing buffer to increase or restore GSH levels.
At the end of each experiment, lungs were snap-frozen for GSH/GSSG analysis. In
experiments with GSEt-perfused lungs, the lungs were flushed with 20 ml buffer
without GSEt to remove any GSEt that had not been incorporated by the lung tissue.
All experiments were approved by the appropriate ethical committees.
Measurement of GSH and GSSG
The snap-frozen superior lobe of the left lung was crushed in liquid nitrogen using a
mortar and pestle; the resulting powder was divided between two eppendorf tubes. In
one tube, a mixture of 1 M HClO4 with 2 mM EDTA was added (1 ml per 250 mg
powder) to assay total glutathione (GSH + GSSG), while the same mixture
supplemented with 10 mM N-ethyl maleimide was added to the other tube to assess
levels of oxidized glutathione. After vigorous vortex mixing, the tubes were
centrifuged at 5000 g for 10 min and total and oxidized glutathione concentrations in
the supernatants were determined with a modified version (19) of the glutathione
reductase-DTNB recycling assay according to Akerboom et al. (20). Values were
expressed in nmole per g tissue (wet weight).
Statistics
Data are expressed as mean ± SEM. For all experiments, significance calculations
were performed using the two-tailed Student’s t-test. In the case of dose-response
curves, maximum responses (Emax) were tested for significance. Differences were
considered statistically significant if P < 0.05.
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Results
Effect of the early asthmatic reaction on lung GSH and GSSG levels
Immediately after the onset of an EAR as induced by respiratory OVA challenge in
vivo, lungs contained 40% less GSH (P < 0.005) and three-fold more GSSG (P <
0.005) than lungs from identically challenged sham-sensitized guinea pigs (figure 2).
Consequently, the average amount of lung GSSG relative to total glutathione
increased markedly from 5.5% in controls to 22.7% during the EAR (P < 0.0001).
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Figure 2. Effect of an EAR on lung glutathione levels. Sham- or OVA-sensitized
guinea pigs were challenged with an OVA aerosol, after which lungs were harvested
to measure GSH and GSSG. Compared to lungs of sham-sensitized animals, lungs
from OVA-sensitized guinea pigs contained less GSH (white bars), while GSSG
levels (black bars) were increased.
Data are expressed as means ± SEM (N = 8); * P < 0.005
Airway resistance during the EAR in perfused lungs
Challenge of lungs from sham-sensitized animals with OVA in the perfusion set-up
evoked no significant increase in perfusion back pressure (figure 3), while OVA-
challenge of the lungs of sensitized animals markedly increased perfusion back
pressure (P < 0.01). When GSEt (1.0 mM) was present in the buffer, the increase in
resistance of lungs from OVA-sensitized animals was substantially (P < 0.01)
reduced. Notably, GSEt virtually nullified the difference between the OVA-induced
airway responses of the sensitized and the sham-sensitized groups (P = 0.06). Lungs
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of OVA-sensitized animals showed no response to challenge with BSA, while a
subsequent challenge with OVA resulted in typical response (data not shown).
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Figure 3. Effect of an EAR on airway opening pressure (Pao) in the absence or
presence of the GSH donor, GSEt, in the perfusing buffer. Conditions of the
experiment are the same as described for figure 1. White bars, sham-sensitized
animals; black bars, OVA-sensitized animals.
Data are expressed as means ± SEM (N = 7); * P < 0.01; **, P < 0.005
Effect of in vivo GSH depletion with BSO on lung GSH and GSSG levels
BSO treatment of guinea pigs decreased lung GSH levels by 85% (figure 4a, P <
0.005), while GSSG levels were no longer detectable. GSEt-perfusion restored lung
GSH and GSSG values in BSO-treated lungs to 48 and 50%, respectively, of the
levels in non BSO-treated animals (figure 4b). Since in the GSEt treated group the
differences in GSH and GSSG levels between BSO-treated and control animals were
not significant (P = 0.087), GSEt perfusion actually eliminated the effects of BSO
treatment.
Effect of GSH depletion in vivo on histamine reactivity of isolated lungs
Histamine induced dose-dependent contractions of control lungs, reaching a
maximum Pao of 9.2±1.4 kPa following 10-5 mole of histamine. This value was not
changed by concomitant GSEt perfusion. Compared to the controls, GSH-depleted
lungs from BSO-treated animals were hyperresponsive to histamine (figure 5a),
reaching a maximum Pao of 13.0±1.3 kPa (P < 0.05). GSEt in the perfusing buffer
prevented BSO-induced increases in histamine responsiveness (figure 5b).
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Figure 4. Effect of BSO treatment and GSEt perfusion on lung glutathione levels. A.
BSO treatment decreased guinea pig lung GSH levels (white bars; N = 10) by 85%
compared to control animals (N = 8), while GSSG (black bars) in BSO-treated
animals could no longer be detected. B. Perfusion with GSEt partially restored lung
GSH and GSSG levels (N = 7). Data are expressed as means ± SEM. n.d., not
detectable; n.s., not significantly different; * P < 0.005
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Figure 5. A. Effect of GSH depletion on histamine reactivity of isolated lungs.
Histamine-induced contractions in isolated lungs of GSH-depleted guinea pigs were
higher than those in lungs of control animals. Data are expressed as means ± SEM
(BSO, N = 10; control, N = 8). Triangles, controls; squares, BSO-treated animals. * P
< 0.05. B. Effect of supplementary GSH on histamine responses of GSH-depleted
guinea pig lungs. Perfusion with the GSH donor, GSEt (1 mM), prevented
hyperresponsiveness of lungs depleted of GSH by prior BSO treatment. Data are
expressed as means ± SEM (N = 7, both groups). Triangles, controls; squares, BSO-
treated animals.
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Discussion
This study shows that GSH is markedly depleted and GSSG is significantly increased
during an EAR. In view of this shifted redox balance, an EAR is very likely to be
accompanied by massive oxidative stress. Our data are the first report that GSH
levels are acutely decreased during an experimental EAR. The acute GSH depletion
and bronchoconstriction that accompany the allergic reaction are probably causally
related, since perfusion with the GSH donor, GSEt, prevented allergen-induced
airway smooth muscle contraction. In addition, lungs depleted from GSH by BSO
treatment were hyperresponsive to histamine; the latter effect could be reversed by
addition of GSEt.
The occurrence of oxidative stress during the primary EAR is a remarkable finding,
since inflammatory cells have not yet been recruited into the lungs as a result of prior
respiratory allergen challenge. Although the source of the oxidative burst is
unknown, histamine release by allergen-activated mast cells, a major feature of an
EAR, is known to be accompanied by acute oxidative stress associated with
enzymatic and non-enzymatic peroxidation reactions in vitro (21). Moreover,
histamine release from cultured rat mast cells appeared to require oxidation of
arachidonic acid by oxygen-centered free radicals (22). Allergen-induced mast cell
activation could thus result in a self-amplifying cascade in which oxidative stress and
the release of the smooth muscle contractant histamine are key events. Interestingly,
it was shown that the formation of histamine-releasing substances from arachidonic
acid by oxygen-centered free radicals can be inhibited by several free radical
scavengers, including GSH (22). This is in line with our findings that a cell
permeable GSH-precursor inhibited airway contraction during the EAR. The identity
of the oxidative arachidonic acid products is obscure. A candidate that has gained
increasing attention in the field of oxidative stress markers is 8-iso-prostaglandin F2α
(8-iso-PGF2α); the latter product is a mainly non-cyclo-oxygenase-derived
prostaglandin that is abundantly produced during oxidative stress (23). 8-Iso-PGF2α
is an airway smooth muscle contractant (24) and was found to be elevated in plasma
(25) and exhaled breath condensate (26) of asthmatics. Hence, 8-iso-PGF2α is
possibly involved in the EAR and this is subject of our current investigations.
Airway responses to the contractile agent that was studied in the current paper,
histamine, were shown to be increased by GSH depletion. Since histamine is
released from allergen-activated mast cells, the increased responsiveness to
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histamine under conditions of low GSH suggests an additional way to explain
increased airway contraction during an EAR.
Apart from affecting the production or action of smooth muscle contractile agents,
GSH may also influence relaxant substances. GSH is known to enhance the
bioavailability of nitric oxide (NO) (27), a major airway smooth muscle relaxant that,
moreover, antagonizes histamine release by mast cells (28). Thus, depletion of GSH
may increase airway contractility by hampering the effects of NO. Another airway
smooth muscle relaxant is PGE2. PGE2 synthesis was found to be downregulated in
renal homogenates by limiting GSH concentrations (29). Unfortunately, an
interference of GSH with the relaxant compounds NO and PGE2 could not be
substantiated because they were undetectable in the lung perfusate samples
(experiments and data not shown).
An earlier report showing that total glutathione levels in lung lavage fluid are higher
in stable asthmatics than in healthy subjects (12) seemingly contrasts with the present
findings. However, acute depletion of GSH generally stimulates GSH production and
results in enhanced GSH levels at a later stage in various cells and tissues (17),
including cultured human lung epithelial cells (30). Thus, the enhanced GSH levels
in stable asthmatics are likely to be the result of GSH depletion by the local
inflammatory cells and possibly by preceding exacerbations.
This paper has shown that airway GSH levels in an animal model of an EAR are
acutely decreased. Furthermore, decreased GSH is associated with enhanced airway
responses. This could be due to interference of GSH with different mechanisms, in
particular an interference at the level of airway smooth muscle reactivity to
histamine. We speculate that maintenance of a physiologic redox balance in the
airways during asthma could be an interesting approach for innovative therapy.
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Abstract
Since an allergen-induced early asthmatic reaction was found to be accompanied by
oxidative stress and since levels of the endogenous antioxidant, glutathione,
reportedly can be enhanced by a whey-supplemented diet (UWPC), it was
investigated whether UWPC could alleviate allergen-induced lung contractions. To
this end, guinea pigs were sensitized to ovalbumin (OVA) and fed water or UWPC
in addition to standard lab chow. Blood samples were taken on several days after
sensitization to measure serum levels of allergen-specific IgG1 and IgG2. After three
weeks, lungs were isolated and perfused with buffer containing the allergen. Airway
contractions were assessed, and several airway contractile and relaxant mediators, as
well as indicators for oxidative stress, were measured in the lung effluent. Liver
glutathione levels were determined to control for the GSH-enhancing effect of
UWPC. UWPC feeding significantly enhanced liver glutathione by 20%, and
significantly decreased lung contractions in sensitized animals by 45%. IgG levels
were not altered by UWPC. The airway relaxant, PGE2, was increased upon OVA-
challenge in OVA-sensitized groups, and tended to be decreased by UWPC. The
indicator of oxidative stress and airway contractile mediator, 8-iso-PGF2α, was also
increased upon OVA challenge in OVA-sensitized groups, and tended to be further
increased by UWPC. Another indicator of oxidative stress, thiobarbituric reactive
substances (TBARS), was also increased in OVA-sensitized animals as compared to
saline-sensitized controls. UWPC-feeding did not alter the levels of the OVA-
sensitized group but tended to increase the TBARS levels of the saline-sensitized
group. In conclusion, UWPC feeding reduced lung contractility, but this was
probably not through an antioxidant effect of UWPC.
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Introduction
Reactive oxygen species play a prominent role in inflammatory lung diseases,
including asthma. Although the lungs are equipped with a variety of enzymatic and
non-enzymatic anti-oxidant systems, there are indications that asthma is associated
with a local oxidant / antioxidant imbalance, particularly during exacerbations of the
disease. One of the most prominent endogenous antioxidants of the airways is
glutathione (GSH). We have previously shown in a guinea pig model of allergic
asthma that an allergen-induced early asthmatic response (EAR) is paralleled by
markedly decreased lung GSH levels (chapter 4). In an isolated lung perfusion set
up, we also demonstrated that the allergen-induced airway contractions could be
prevented by a cell-permeable GSH analogue in the perfusing buffer (chapter 4).
To demonstrate the therapeutic relevance of these findings, it would be of interest to
enhance glutathione levels of the airways in vivo. Administration of GSH, however,
is not an effective way to increase tissue GSH levels (1), while the GSH prodrug,
cysteine, is not useful because of its toxicity (2, 3). The cysteine derivative, N-
acetylcysteine, is not toxic but its oral bioavailability is poor (see (4) for a review).
An alternative way to enhance GSH levels in vivo is the food supplement
undenatured whey protein concentrate (UWPC). UWPC is a mixture of proteins and
peptides rich in γ-glutamylglycine, a dipeptide that is known to increase intracellular
GSH (5). Interestingly, a recent case report has referred to a patient with obstructive
lung diseases whose improvement of pulmonary function and increase in plasma
GSH levels could be correlated to UWPC intake (6).
In the present study, the effect of UWPC was assessed using the above described ex
vivo guinea pig model of allergic asthma. Guinea pigs were fed UWPC as a
supplement from three days before sensitization with allergen until sacrifice, three
weeks later. At that time, allergen-induced contractions of isolated lungs, as well as
lung perfusate levels of indicators of oxidative stress and a number of contractile and
relaxant arachidonic acid metabolites were measured. Furthermore, total glutathione
content of the liver was measured. Blood samples were taken before and at regular
intervals after sensitization to determine allergen-specific IgG levels in serum.
Methods
Animals
Male specific pathogen-free Dunkin Hartley guinea pigs (Harlan Nederland, Horst,
The Netherlands), weighing 200 – 250 g at the start of the experiments were housed
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under controlled conditions. Water and commercial chow were allowed ad libitum.
Ovalbumin sensitization and challenge
Animals were sensitized on day 0 by injecting a mixture of 20 μg ovalbumin (OVA;
grade V, Sigma, St Louis, MO) and 200 mg of the adjuvant, Al(OH)3 (Merck,
Darmstadt, Germany), in 1.0 ml saline. Al(OH)3 in saline was used for the controls.
Each animal received six injections: 0.5 ml was injected intraperitoneally, and five
injections (0.1 ml each) were given subcutaneously in the axillar and inguinal
regions and in the nuchal area. On day 20, airways were isolated and challenged
with OVA as described in the section Tracheally perfused lung preparation.
Diet regimen
UWPC was gently dissolved in sterile tap water at a concentration of 0.5 g/ml
immediately before use. It was administered per os using a syringe with a
polyethylene tubing that was placed at the back of the mouth of the animal. Slowly
emptying the syringe made the animals swallow spontaneously. Each animal
received 5 ml of whey solution twice daily, with 7 h between administrations.
Controls received sterile tap water following the same administration regimen.
Whey administration started three days before sensitization.
Tracheally perfused lung preparation
Tracheal perfusion was performed on day 20 after sensitization as previously
described (7). Guinea pigs were anesthetized by intraperitoneal injection of 10%
(w/v) urethane (2 ml/100 g body weight). When a sufficient level of anesthesia was
achieved, a 2-cm-long polyethylene tube (1.67 mm I.D., 2.42 mm O.D.) was inserted
into the trachea and the abdominal cavity was opened to inject 500 U of heparin into
the vena cava and to severe and the abdominal aorta 3 min later. Then, the thoracic
cavity was opened to remove heart and lungs en bloc. The lungs were dissected free
and hung in a plexiglas box at 37ºC and 100% relative humidity. The lungs were
perfused via the tracheal cannula with a phosphate-buffered physiological solution
(pH 7.4) of the following composition: NaCl 137 mM, CaCl2 1.8 mM, MgCl2 1.05
mM, KCl 2.68 mM, NaHCO3 0.6 mM, NaH2PO4 0.13 mM, and Na2HPO4 0.896
mM. The buffer was warmed to 45ºC and pumped at a rate of 2 ml/min through a
bubble trap before being cooled to 37ºC for the actual lung perfusion. When the
lungs had fully expanded, the buffer was allowed to exit the lungs through multiple
small holes made in the pleura. The “back pressure” resulting from the perfusion
(airway opening pressure, Pao) was recorded from a side tap at the tracheal cannula
with the use of a pressure transducer. We have previously shown that during
continuous flow, the Pao reflects the contractile state of the lung (7). Subsequently,
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lungs were perfused for 10 min to give a stable baseline pressure. At that time,
different compounds were added to the buffer to test their effect on airway resistance
as described hereafter.
For the induction of an EAR, 3.0 mg OVA in 0.30 ml perfusion buffer was injected
in the perfusion system as described earlier (Chapter 4).
Measurement of liver glutathione
After lung isolation, a liver lobe was snap-frozen in liquid nitrogen from each animal
to be stored at -80ºC until analysis. Each lobe was then crushed in liquid nitrogen
using a mortar and pestle; the resulting powder was transferred to an eppendorf tube
and a mixture of 1 M HClO4 with 2 mM EDTA was added (1 ml per 250 mg
powder). After vigorous vortex mixing, tubes were centrifuged at 5000 g for 10 min
and total glutathione (GSH + GSSG) concentrations in the supernatants were
determined with a modified version (8) of the glutathione reductase-DTNB recycling
assay according to Akerboom et al. (9). Values were expressed in nmol per mg
tissue (wet weight).
OVA-specific serum IgG
Blood samples (± 350 μl each) were collected from a femoral vein on days -2, 5, 12,
18, and 20. Blood was allowed to clot for 30 min at room temperature before being
centrifuged at 20,000 g for 10 min. Serum was collected and stored at -20ºC until
analysis. IgG1 and IgG2 antibody responses to OVA were assayed with an ELISA.
Flat-bottom microplates (96-wells, Maxisorp, Nunc A/S, Roskilde, Denmark) were
coated with 100 μg OVA per ml buffer (38 mM Na2CO3, 43 mM KH2PO4; pH 9.5)
for 60 min at 37°C. After washing with 0.05% Tween20 in PBS, free binding sites
were blocked with 1% BSA (Boehringer – Mannheim) in ELISA buffer (50 mM
Tris, 2 mM EDTA, 136.9 mM NaCl, 0.05% Tween20; pH = 7.2) at 37°C for 60 min.
After removal of the blocking buffer and washing, serially diluted serum samples
were incubated for 2 h at 37°C. After washing, the plates were incubated with
horseradish peroxidase-conjugated goat anti-guinea pig IgG1 and IgG2 (diluted
1/10,000 and 1/3,000 , respectively; Bethyl laboratories, Montgomery, TX) in
ELISA buffer with 0.5% BSA. After washing, O-phenylene diamine dihydrochloride
(0.4 mg/ml; Sigma) in PBS containing 0.012% hydrogen peroxide was added. The
reaction was stopped after 10 min through addition of 4 M H2SO4. Optical density
was measured at 490 nm with a Titrek Multiscan (Flowlabs, Irvine, UK). Serum
samples that had been pre-incubated (120 min, 37°C) with UWPC (25 ng/ml)
underwent the same procedure to control for cross-reactivity of OVA-specific IgG
with UWPC, using preincubation with a similar amount of OVA as a positive
control.
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Effluent analysis
Buffer that exited the lungs during the development of contractile responses was
collected. In the case of non-sensitized animals, buffer was collected at the
corresponding time. Samples were snap frozen in liquid nitrogen and stored at -80ºC
until analysis. Within three weeks after collection, levels of PGE2, LTC4/D4/E4, and
8-iso-PGF2αwere measured in the samples with commercial EIA kits (Cayman, Ann
Arbor, MI for 8-iso-PGF2α; Amersham Pharmacia Biotech for the LT as well as for
PGE2 analysis) according to manufacturer’s instructions. Samples (100 μl) for
measurement of TBARS were acidified to pH 2 - 3 with 10 μl 1% (w/v)
trichloroacetic acid. Protein was precipitated by centrifugation and 100 μl
supernatant was allowed to react with an equal volume of thiobarbituric acid (0.67%,
w/v) for 10 min at 100°C. After cooling to room temperature, the absorbance at 532
nm was measured photometrically (10). Perfusion buffer was treated the same way
to serve as a blank.
Data analysis and statistics
Tracings reflected the increase in airway opening pressure as a function of time. For
each animal, the area under the curve was calculated from 50 s to 150 s after
addition of allergen to the buffer. If data were normally distributed, they were
analyzed with a one-way ANOVA followed by the LSD post-hoc test for multiple
comparisons. If data were not normally distributed, they were analyzed with the
Kruskal-Wallis test. P-values < 0.05 were considered to reflect significant
differences. The numbers of animals studied were 9 in both saline-sensitized groups,
7 in the water-fed OVA-sensitized group, and 8 in the UWPC-fed OVA-sensitized
group.
Results
Liver glutathione
Livers from control-fed guinea pigs contained 2.3 nmol of total glutathione/mg wet
tissue. UWPC-feeding induced a 20% increase of total glutathione content of the
liver (figure 1; P < 0.05).
Airway contractions
In the lungs from non-sensitized groups, OVA perfusion did not change airway
opening pressure from either control-fed or UWPC-fed animals. In contrast, OVA
provoked clear airway contractions in lungs from sensitized animals (figure 2).
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Figure 1. Levels of total glutathione (GSH + GSSG) in livers from water- (white bar)
and UWPC- (black bar) fed guinea pigs. UWPC treatment enhanced liver levels of
total glutathione as compared to livers of water-fed guinea pigs. N = 11 in the water-
fed and 10 in the UWPC-fed group. Bars indicate mean ± SEM; * P < 0.05.
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Figure 2. Lung contractility of isolated and perfused guinea pig lungs during the
allergen-induced early asthmatic response. OVA challenge induced contractions in
lungs from OVA-sensitized (white bars), but not saline-sensitized (black bars) guinea
pigs, but the OVA-induced contractions were substantially reduced in the UWPC-fed
group as compared to the water-fed group.
Bars indicate mean ± SEM; * P < 0.05.
UWPC-feeding reduced the allergen-induced airway contractions in sensitized
animals by 45% as compared to sensitized animals that had received water (P <
0.05).
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OVA-specific serum IgG
OVA-specific IgG antibodies could not be detected in sera from sham-sensitized
animals (not shown). In sera of OVA-sensitized animals, a time-dependent increase
in OVA-specific IgG1 and IgG2 was observed (figure 3). UWPC-feeding of
sensitized animals did not alter their IgG plasma levels as compared to the sensitized
water-fed group. Furthermore, pre-incubation of serum samples with UWPC did not
affect binding of serum IgG to OVA-coated plates, while pre-incubation with OVA
blocked the binding completely (data not shown).
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Figure 3. IgG1 (panel A) and IgG2 levels (panel B) in 1280-fold diluted serum of
water-fed (white bars) and UWPC-fed (black bars) guinea pigs after sensitization to
OVA. A time dependent, but feeding independent  increase in IgG1 and IgG2 levels
was observed.
Bars indicate mean ± SEM.
Effluent analysis
Allergen challenge of lungs from the water-fed sensitized animals increased PGE2 in
lung perfusates, as compared to non-sensitized animals (P < 0.05, figure 4). UWPC-
treatment decreased PGE2 levels in perfusates of sensitized guinea pig lungs by 55%
as compared to the corresponding water-fed control group. This effect, however, did
not reach statistical significance.
Histamine and leukotrienes were undetectable in almost all effluent samples both of
saline- and OVA-sensitized groups.
Allergen challenge doubled 8-iso-PGF2α levels in lung perfusate of water-fed
sensitized animals, as compared to water-fed non-sensitized animals (P < 0.05,
figure 5). UWPC-feeding did not significantly alter the 8-iso-PGF2α levels, although
they tended to be higher than those of the corresponding water-fed control group.
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Figure 4. PGE2 levels in perfusate samples taken during the allergen-induced early
asthmatic response of isolated guinea pig lungs. OVA challenge increased PGE2
formation in lungs from OVA-sensitized (black bars) animals as compared to saline-
sensitized controls (white bars), but less so upon UWPC feeding.
Bars indicate mean ± SEM; * P < 0.05.
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Figure 5. 8-iso-PGF2α levels in perfusate samples taken during the allergen-induced
early asthmatic response of isolated guinea pig lungs. OVA challenge increased 8-iso-
PGF2α formation in lungs from OVA-sensitized animals (black bars) as compared to
saline-sensitized controls (white bars), and UWPC feeding tended to further increase
these levels.
Bars indicate mean ± SEM; * P < 0.05.
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Figure 6. Levels of thiobarbituric acid reactive substances (TBARS) in perfusate
samples taken during the allergen-induced early asthmatic response of isolated guinea
pig lungs. OVA challenge increased TBARS formation in lungs from water-fed OVA-
sensitized animals (left-hand black bar) as compared to water-fed saline sensitized
controls (left-hand white bar). After OVA-challenge, TBARS levels in the UWPC-fed
saline-sensitized group (right-hand white bar) and in the UWPC-fed OVA-sensitized
group (right-hand black bar) were similar as those in the water-fed OVA-sensitized
group. Bars indicate mean ± SEM; ** P < 0.01; * P < 0.05.
OVA challenge doubled absorbance due to TBARS in samples from OVA-sensitized
water-fed group, as compared to the saline-sensitized group (P < 0.01, figure 6).
UWPC feeding tended to increase TBARS levels of the saline-sensitized UWPC-fed
group, and did not alter TBARS levels of the OVA-sensitized group, as compared to
the corresponding water-fed group.
Discussion
This study has demonstrated that feeding a UWPC food supplement protects against
early allergen-induced airway contractions in a guinea pig model of asthma (figure
2). Since serum levels of allergen-specific IgG1 and IgG2 were similar in UWPC-fed
and water-fed animals, the reduced airway contractions could not be explained by an
effect of UWPC on the production of these antibodies that reportedly mediate
immediate type hypersensitivity in the guinea pig (11) (figure 3). Liver glutathione,
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however, was increased by UWPC feeding (figure 1), suggesting increased GSH
levels in other tissues, including the lungs, as well. If so, UWPC treatment may have
decreased allergen-induced contractions via a similar mechanism as perfusion with
GSH or a GSH-donor, which was earlier shown to relax airway smooth muscle
(Chapter 3) and prevent allergen- and histamine-induced airway contractions
(Chapter 4). Unfortunately, lung GSH levels could not be measured reliably, since
the contractile state of the airway influenced the amount of buffer in the lungs,
making it hard to relate GSH content to tissue weight.
The mechanism by which UWPC decreased the allergen-induced airway
contractions remains elusive. The observation that an early asthmatic response is
associated with decreased GSH levels and a disturbed GSH/GSSG balance in guinea
pig lungs (Chapter 4) strongly suggested that allergen-induced airway contractions
are accompanied by oxidative stress in the guinea pig. This suggestion is
substantiated by observations that two indicators of oxidative stress, 8-iso-PGF2α
(12) (figure 5) and TBARS (13) (figure 6), were increased in the effluent of lungs
during the early asthmatic response.
It is conceivable that allergen-induced oxidative stress modulates the production of
relaxing or contractile mediators. In this study, OVA challenge of lungs from
sensitized animals increased effluent levels of the airway relaxant, PGE2, as
compared to saline-sensitized controls. Feeding UWPC tended to reduce the PGE2
production. This is consistent with the putatively increased antioxidant action of
UWPC feeding, since PGE2 production is known to be stimulated by oxidative stress
(14) and inhibited by a ROS-scavenger (15). Alternatively, since post-OVA
challenge PGE2 levels were higher in OVA-sensitized than in saline-sensitized
groups, the amount of PGE2 production may relate to the degree of airway
contraction. Indeed, it has been shown by others that allergen-induced contractions
of guinea pig trachea were paralleled by histamine release, and were followed
somewhat later by PGE2 release (16). Thus, PGE2 synthesis may be stimulated by
airway contractions to counteract excessive airway constriction. Accordingly, the
lesser contraction in the UWPC-fed groups would result in less PGE2 synthesis
(figure 4).
The contractile mediators, histamine and leukotrienes, which are known to be
released upon allergen-induced mast cell activation (17) and whose release is
potentiated by oxidative stress (18), appeared hardly or not at all detectable in the
perfusate of OVA-challenged lungs from sensitized animals, regardless of the
feeding. Possibly, the flow rate (2 ml/min) of the perfusion buffer caused too much
dilution of mediators to detect them in the perfusate.
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The isoprostane, 8-iso-PGF2α, however, could be measured unambiguously in the
perfusate. Besides being an indicator of oxidative stress as already addressed above,
8-iso-PGF2α is a potent airway contractant (19-21). Indeed, OVA challenge of
sensitized lungs significantly increased 8-iso-PGF2α release, suggesting that the
OVA-induced contraction could have been mediated in part by this compound.
UWPC feeding, however, did not reduce 8-iso-PGF2α levels in the perfusate but, on
the contrary, tended to cause a slight increase. These seemingly conflicting data may
be explained by assuming that UWPC feeding decreases the contractile reactivity to
8-iso-PGF2α. Earlier findings that GSH can decrease tracheal hyperreactivity to
another contractile agent, histamine (chapter 3), while GSH depletion can render the
airways hyperreactive to this mediator (chapter 4), provide supportive evidence for
this assumption.
Assuming that UWPC increases lung GSH levels, an explanation for the failure of
UWPC to decrease 8-iso-PGF2α levels is the dual action of GSH on 8-iso-PGF2α
synthesis. GSH as an antioxidant may inhibit all oxidative steps in the pathway of 8-
iso-PGF2α formation. The last step, however, is a reduction of a bicyclic
endoperoxide (22). Consequently, the last step in the formation of 8-iso-PGF2α can
be promoted by GSH (23). Thus, this dual effect formation may explain the lack of
effect of UWPC on the levels of 8-iso-PGF2α and may have obscured the capacity of
UWPC to diminish oxidative stress. To address this possibility, TBARS were
measured in the same samples as used for 8-iso-PGF2α measurement. Like 8-iso-
PGF2α, TBARS are endoperoxide breakdown products, but their formation does not
require GSH. TBARS levels, however, appeared increased in both OVA-sensitized
groups and clearly tended to be increased in the saline-sensitized, UWPC-fed group
(figure 6). Provided that TBARS are an adequate representation of oxidative stress
(24), these data suggest that UWPC has no anti-oxidant action in the lungs and
rather induces oxidative stress in this organ. Since saline-sensitized, UWPC-fed
animals had no OVA-specific antibodies in their serum, the presumed oxidative
stress in the lungs from these animals could not have resulted from immune complex
formation after OVA challenge. Moreover, the presumed UWPC-induced oxidative
stress appeared not additive to the oxidative stress induced by OVA-challenge of
sensitized animals. Therefore, it is unclear how the oxidative stress was generated
and how UWPC significantly diminished the early asthmatic reaction without
diminishing oxidative stress in the lungs.
In conclusion, although UWPC feeding reduced lung contractility, there are no data
to substantiate that this was through an antioxidant effect of UWPC.
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Abstract
It is becoming increasingly clear that oxidative stress contributes to the pathogenesis
of asthma. Therefore, this study addressed the question whether supplements of the
endogenous antioxidant, glutathione (GSH), in a murine allergic asthma model
would alleviate features of asthma. To this end, sensitized mice received aerosols of
the GSH-donors, glutathione-ethyl ester (GSEt) or N-acetylcysteine, before or
during respiratory allergen challenges, or during cholinergically provoked airway
contractions one day after the last allergen challenge. Lung GSH levels were
measured shortly after allergen challenge or after cholinergic provocation, and
broncho-alveolar lavages (BAL) were performed to study the effect of GSH
supplements on the influx of inflammatory cells into the airways. GSEt was found to
decrease allergen-induced cholinergic airway hyperresponsiveness when given in
combination with methacholine. However, when given before or during allergen
challenge, both GSH-donors failed to decrease subsequent methacholine-induced
airway contractility, BAL cell numbers, or increase lung GSH levels. In addition,
allergen challenges of sensitized mice did not decrease lung GSH levels, suggesting
that these challenges do not cause oxidative stress. Therefore, it is concluded that the
failure of GSH-donors to decrease allergen-induced cholinergic hyperreactivity
when given before or during allergen challenge may be explained by the lack of
oxidative stress during the allergen challenge. In view of the oxidative stress upon
allergen challenge observed earlier in the guinea pig and the importance of oxidative
stress in the pathology of allergic asthma in humans, the guinea pig may be a more
suitable species than the mouse to study oxidative stress in asthma.
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Introduction
Asthma is characterized by a chronic inflammatory condition of the lungs and
reversible airflow obstruction. The inflammation is mild during remissions, but
during exacerbations, inflammatory cells can produce large amounts of mediators,
including reactive oxygen species (ROS). Exaggerated production of ROS may
deplete anti-oxidant systems, leading to tissue damage and a disturbed biochemistry.
This condition is referred to as oxidative stress and is increasingly appreciated in
asthma (1, 2). It is still unclear how oxidative stress in asthma affects lung levels of
glutathione (GSH), a prominent endogenous anti-oxidant. We recently demonstrated
in a guinea pig model of asthma that allergen challenge induced GSH depletion of
lung tissue during the early asthmatic response. In addition, supplementing GSH
during an early asthmatic response in a lung perfusion model could prevent acute
allergen-induced contractions. Besides allergen-induced acute airway contractions,
airflow obstruction in asthmatics is manifest by exaggerated responses to contractile
stimuli. This airway hyperreactivity (AHR) has a chronic character. Like allergen-
induced acute airway contractions, AHR is generally considered to be a consequence
of the inflammatory state of the lungs (3). Although the events contributing to its
development are still ill understood, previous experiments in our lab have shown
that isolated perfused lungs from GSH-depleted guinea pigs were hyperresponsive to
histamine. In addition, perfusion of the lungs with GSH-ethyl ester (GSEt) prevented
this hyperresponsiveness. Since these data suggest that GSH depletion may underlie
AHR, the current study was done to address the question to what extent nebulization
of GSH or GSH-precursors could counteract the development of airway
inflammation and AHR in an in vivo murine model of asthma.
Methods
Animals
Animal care and use was in accordance with the guidelines of the local ethical
committee for animal experiments. Specific pathogen-free male BALB/c mice (6
weeks) were obtained from the Utrecht University animal facilities department
(Utrecht, The Netherlands) or from Charles River (Someren, Netherlands; study of
protocol IV). The animals were housed in macrolon cages in a laminar flow cabinet
and provided with food and water ad libitum.
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Ovalbumin sensitization and challenge
All animals were sensitized with an intraperitoneal injection (100 μl) of a mixture of
20 μg ovalbumin (grade V, Sigma, St Louis, MO; OVA) and 200 mg of the
adjuvant, Al(OH)3, in 1 ml saline on days 0 and 7. On days 30, 33 and 36, the
animals were given a challenge through inhalation of a nebulized OVA solution
(1%, w/v) for 30 min. Control animals received saline instead of OVA. The aerosol
(particle size 2.5 - 3.1 μm) was generated in a plexiglas exposure chamber with a
Pari LC star nebulizer (Pari Respiratory equipment, Richmond, VA, USA) that was
driven by compressed air (6 l/min).
Intervention with thiol compounds
Thiol compounds GSEt or N-acetyl cysteine (NAC) (Sigma, St. Louis, MO, USA)
were nebulized in the above-mentioned nebulizer. Thiols were dissolved at 100 mM
in saline; each solution was adjusted to pH 7. Controls received vehicle.
Four treatment protocols were tested:
I. GSEt aerosol for 5 min, 6 h before each OVA or saline challenge.
II. GSEt aerosol for 5 min, 10 min before each OVA or saline challenge.
III. Aerosol of a mixture of NAC and OVA for 30 min during each challenge.
IV. GSEt together with methacholine during provocation of airway contractions,
24 hours after the last OVA aerosol.
In protocols I and II, each group consisted of three animals, while in protocols II and
IV, eight animals per group were used.
Measurement of airway responsiveness
Twenty-four hours after the last allergen challenge, airway responsiveness was
measured in conscious, unrestrained mice using barometric whole-body
plethysmography (Buxco, EMKA Technologies, France). Enhanced pause (Penh)
was taken as a measure of airway responsiveness, as described in detail previously
(4). Mice were exposed to increasing concentrations of nebulized methacholine
(acetyl-β-methylcholine chloride, Sigma, St. Louis, MO, USA; 1.6 - 13 mg/ml
saline) in a plexiglas Buxco chamber. Each dose of methacholine was nebulized for
3 min and followed by a 3-min-period during which airway responses were
recorded.
Broncho-alveolar lavage
Following airway responsiveness measurements, mice received a lethal dose of
pentobarbitone sodium (Euthesate® 0.6 g/kg body weight, intraperitoneally). The
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trachea was trimmed free of connective tissue, and a small incision was made to
insert a cannula in the trachea. Via this cannula, the lavage was performed by filling
the lungs with 1.0 ml sterile saline of 32°C. and withdrawing it after 10 seconds. The
cell suspension was collected in a plastic tube on ice. This procedure was repeated
three times to obtain a pooled cell suspensions from each animal. The cells were
spun down by centrifugation at 400 g for 5 minutes at 4°C and resuspended in 150 μl
ice-cold PBS. A sample of this was stained with Türk's solution and counted in a
Bürker-Türk bright-line counting chamber to calculate the total number of cells.
Another sample was used to prepare cytospin preparations. These were air dried,
fixed, and stained with Diff-Quik (Merz + Dade A.G., Düdingen, Switzerland). The
cells were differentiated morphologically into alveolar macrophages, eosinophils,
lymphocytes and monocytes, and neutrophils by light microscopical observation.
Glutathione measurements
After the broncho-alveolar lavage, lungs were isolated and snap frozen in liquid
nitrogen until analysis for GSH and oxidized glutathione (GSSG). To that end, lungs
were crushed in liquid nitrogen using a mortar and pestle; the resulting powder was
divided between two eppendorf tubes. To one tube, a mixture of 1 M HClO4 with 2
mM EDTA was added (1 ml per 250 mg powder) to assay total glutathione (GSH +
GSSG), while the same mixture supplemented with 10 mM N-ethyl maleimide
(NEM) was added to the other tube to assess levels of oxidized glutathione. After
vigorous vortex mixing, the tubes were centrifuged at 5000 g for 10 min and total
and oxidized glutathione concentrations in the supernatants were determined with a
modified version (5) of the glutathione reductase-DTNB recycling assay according
to Akerboom et al. (6). Values were expressed in nmol per g tissue (wet weight).
Influence of OVA challenge on lung GSH/GSSG levels
To investigate the effect of OVA challenge on lung GSH and GSSG levels, animals
were sacrificed with pentobarbitone sodium (Euthesate® 0.6 g/kg body weight,
intraperitoneally) immediately after the first or the third OVA aerosol, or 24 hours
after the third challenge. Lungs were quickly isolated and snap-frozen in liquid
nitrogen to be assayed for GSH and GSSG levels. Eight animals were used per time
point.
Statistics
Dose response curves were statistically analyzed using a general linear model of
repeated measures test, followed by the LSD post-hoc test for multiple comparisons.
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In case the GSH levels and BAL cell counts were normally distributed, they were
analyzed with a one-way ANOVA followed by the LSD post-hoc test for multiple
comparisons. In case data were not normally distributed, they were analyzed with
the Kruskal-Wallis test. Differences were considered statistically significant if P <
0.05.
Results
In animals that were treated with vehicle instead of GSEt 6 h before each challenge,
saline challenge resulted in a normal dose-dependent increase of airway reactivity to
methacholine (figure 1A and B).
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Figure 1. Methacholine-induced airway contractions in OVA-sensitized mice that
received vehicle (white bars) or GSEt (black bars) 6 h before each challenge with
saline (panel A) or OVA (panel B). OVA challenges induced significant (P < 0.05)
hyperresponsiveness as compared to saline challenges. GSEt-treatment had no
influence on airway contractions of saline-challenged mice; neither did it alter OVA-
induced hyperresponiveness.
Bars indicate mean ± SEM
Compared to saline challenge, OVA challenge caused cholinergic hyper-
responsiveness (P < 0.05). GSEt treatment did not affect cholinergic responsiveness
as compared to the corresponding vehicle treatment.
Lungs from the vehicle-pretreated, saline-challenged mice contained 300 and 90
nmol/g wet tissue weight GSH and GSSG, respectively (figure 2). These levels were
not significantly changed by GSEt pretreatment or OVA challenge.
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Figure 2. GSH (white bars) and GSSG (black bars) levels of lung tissue from OVA-
sensitized mice that received vehicle or GSEt 6 h before each challenge with saline or
OVA. GSEt-treatment did not increase lung GSH of both saline- and OVA-challenged
mice. Bars indicate mean ± SEM.
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Figure 3. Numbers of inflammatory cells in broncho-alveolar lavage fluid from OVA-
sensitized mice that received vehicle or GSEt 6 h before each challenge with saline or
OVA. OVA challenge significantly (P < 0.01) increased the number of inflammatory
cells. Neither basal cell counts nor the OVA-induced increase of cell numbers were
affected by GSEt-treatment. Dotted bars, macrophages; black bars, eosinophils; white
bars, neutrophils; hatched bars, lymphocytes and monocytes.
Bars indicate mean ± SEM.
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Lung lavage fluid from the vehicle-pretreated, saline-challenged mice contained
normal leukocyte numbers, largely consisting of macrophages (figure 3). OVA
challenge significantly (P < 0.01) increased total cell numbers as particularly caused
by an increased number of eosinophils and, to a lesser extent, lymphocytes and
monocytes. GSEt pretreatment did not significantly change total and differential cell
numbers as compared to the vehicle pretreatment.
0 1.6 3.0 6.3 13
0
1
2
3
4
A
methacholine (mg / ml)
Pe
nh
      
0 1.6 3.0 6.3 13
0
1
2
3
4
B
methacholine (mg / ml)
Pe
nh
Figure 4. Methacholine-induced airway contractions in OVA-sensitized mice that
received vehicle (white bars) or GSEt (black bars) 5 min before each challenge with
saline (panel A) or OVA (panel B). OVA challenges induced significant (P < 0.01)
hyperresponsiveness as compared to saline challenges. GSEt-treatment did not alter
basal airway responses in saline challenged animals or OVA-induced
hyperresponiveness. Bars indicate mean ± SEM.
In animals that were treated with vehicle instead of GSEt 10 min before each
challenge, saline challenge resulted in normal airway reactivity to methacholine
(figure 4A and B) while OVA challenge caused cholinergic hyperresponsiveness (P
< 0.01). GSEt treatment did not affect cholinergic responsiveness as compared to the
corresponding vehicle treatment.
GSH and GSSG levels of lungs from the vehicle-pretreated, saline-challenged mice
were 390 and 16 nmol/g, respectively (figure 5), and were not significantly changed
by GSEt pretreatment or OVA challenge.
Lung lavage fluid from the vehicle-pretreated, saline-challenged mice contained
normal leukocyte numbers, mainly macrophages (figure 6). OVA challenge
significantly (P < 0.01) increased total cell numbers, eosinophils and lymphocytes
and monocytes in particular. GSEt pretreatment did not significantly change total
and differential cell numbers as compared to the vehicle-pretreated groups.
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Figure 5. GSH (white bars) and GSSG (black bars) levels of lung tissue from OVA-
sensitized mice that received vehicle or GSEt 5 min before each challenge with saline
or OVA. GSEt-treatment did not increase lung GSH of either saline- or OVA-
challenged mice. Bars indicate mean ± SEM.
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Figure 6. Numbers of inflammatory cells in broncho-alveolar lavage fluid from OVA-
sensitized mice that received vehicle or GSEt 5 min before each challenge with saline
or OVA. OVA challenge significantly (P < 0.05) increased the number of
inflammatory cells; this increase was not moderated by GSEt-treatment. Dotted bars,
macrophages; black bars, eosinophils; white bars, neutrophils; hatched bars,
lymphocytes and monocytes. Bars indicate mean ± SEM.
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Figure 7. Methacholine-induced airway contractions in OVA-sensitized mice that
received vehicle (white bars) or NAC (black bars) mixed with each saline (panel A) or
OVA (panel B) challenge. OVA challenges induced significant (P < 0.01)
hyperresponsiveness as compared to saline challenges. NAC did not alter airway
contractions of saline-challenged mice, or OVA-induced hyperresponiveness
significantly. Bars indicate mean ± SEM.
In animals challenged with saline aerosol without NAC, airway reactivity to
methacholine was normal (figure 7A), while cholinergic hyperresponsiveness was
observed after challenge with OVA aerosol (figure 7B; P < 0.05). Addition of NAC
to the saline aerosol did not affect the airway response to methacholine. However,
the addition of NAC to the OVA aerosol tended to decrease the
hyperresponsiveness, but the effect was not statistically significant.
Lungs from the saline-challenged mice contained 580 and 47 nmol/g GSH and
GSSG, respectively (figure 8). These levels were not significantly changed by NAC
or OVA challenge.
Airway responses to methacholine and to methacholine mixed with GSEt did not
differ in animals challenged with saline instead of OVA (figure 9A). In OVA-
challenged mice, however, the hyperresponsiveness to methacholine was
significantly attenuated by the addition of GSEt to the methacholine (P < 0.05).
Lungs from mice challenged with methacholine one day after saline challenge
contained 270 and 23 nmol/g GSH and GSSG, respectively (figure 10). These levels
were not significantly changed by the addition of GSEt to the methacholine, or by
the OVA challenge.
OVA challenge significantly (P < 0.01) increased lung leukocyte numbers,
particularly eosinophils and lymphocytes and monocytes, as compared to saline
challenge. The cell numbers were not changed by challenge with methacholine or
methacholine together with GSEt (figure 11).
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Figure 8. GSH (white bars) and GSSG (black bars) levels of lung tissue from OVA-
sensitized mice that received vehicle or GSEt mixed with each saline or OVA
challenge. NAC did not increase lung GSH of either saline- or OVA-challenged mice.
Bars indicate mean ± SEM.
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Figure 9. Methacholine-induced airway contractions in OVA-sensitized mice that
received vehicle (white bars) or GSEt (black bars) mixed with methacholine, 24 h
after the last challenge with saline (panel A) or OVA (panel B). OVA challenges
induced significant (P < 0.01) hyperresponsiveness as compared to saline challenges.
GSEt did not alter normal airway responses in saline-challenged mice, but it
significantly (P < 0.05) decreased the OVA-induced hyperresponsiveness to
methacholine.
Bars indicate mean ± SEM.
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Figure 10.  GSH (white bars) and GSSG (black bars) levels of lung tissue from OVA-
sensitized mice that received vehicle or GSEt mixed with methacholine, 24 h after the
last challenge with saline or OVA. GSEt-treatment did not increase lung GSH of
either saline- or OVA-challenged mice. Bars indicate mean ± SEM.
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Figure 11.  Numbers of inflammatory cells in broncho-alveolar lavage fluid from
OVA-sensitized mice that received vehicle or GSEt mixed with methacholine, 24 h
after the last challenge with saline or OVA. OVA challenge significantly (P < 0.01)
increased the number of inflammatory cells; this increase was not moderated by GSEt
treatment. Dotted bars, macrophages; black bars, eosinophils; white bars, neutrophils;
hatched bars, lymphocytes and monocytes. Bars indicate mean ± SEM.
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Figure 12.  Influence of challenges with saline (panel A) or OVA (panel B) on tissue
levels of GSH (white bars) and GSSG (black bars) in lungs of OVA-sensitized mice at
different time points: 1, immediately after first challenge; 2, immediately after last
challenge; 3, twenty-four hours after the last challenge. Neither GSH levels nor GSSG
levels were significantly altered at any time point. Bars indicate mean ± SEM.
Influence of OVA challenge on lung GSH/GSSG levels
GSH and GSSG levels were not significantly changed immediately after the first or
third OVA challenge, or 24 h after the latter challenge, as compared to challenge
with saline (figure 12A and B).
Discussion
This chapter describes the effects of the GSH-donors, GSEt and NAC, in a murine
model of allergic asthma on airway responsiveness, lung GSH and GSSG levels, and
on the influx of inflammatory cells in the airways.
Administration of the GSH-donors before or during allergen-challenge appeared to
be an inadequate way to moderate airway hyperresponsiveness, although NAC given
during OVA challenge tended to decrease airway hyperresponsiveness (figure 7). In
these studies, the GSH-donors did not increase lung GSH and GSSG levels as
measured one day after the last OVA challenge, immediately after the assessment of
cholinergic airway responses (figures 2, 5, and 8). The unchanged GSH levels and
BAL values one day after the last allergen challenge, and the observation that
addition of GSEt to methacholine decreased cholinergic responsiveness (figure 9)
probably explains the lack of effect of GSH donors on airway contractility when
given before or during allergen challenge. The design of these treatment protocols
was based on previous experiments in guinea pigs, showing a clear drop in lung
GSH levels and an increase in GSSG levels during an OVA-induced early asthmatic
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response. In OVA-sensitized mice, however, allergen challenge did not affect lung
GSH levels (figure 12), suggesting that there is no need to replenish GSH during
allergen challenge in mice. The combined absence of GSH-depletion and a
symptomatic early asthmatic response upon allergen challenge in mice versus the
presence of both features in guinea pigs (chapter 4), apparently reflects a species
difference. This observation also supports the conclusion in chapter 4 that an early
asthmatic response and a decrease of lung GSH are related.
Although GSH supplementation decreased cholinergic responsiveness only when
given during methacholine challenge, the protocols in this paper provide useful
information regarding future studies on administration of GSH donors. The failure of
GSH donors to enhance GSH levels in the lung can be explained in several ways.
Firstly, the assessment of lung GSH levels, 24 h after the last treatment, was
possibly too late to detect a, possibly transient, increase. Additionally, GSH
supplementation may have led to a compensatory feedback inhibition of GSH
synthesis, since GSH is a feedback inhibitor of its own synthesis (7). Secondly, the
effect of GSEt nebulization may have been limited to the epithelium and the sub-
epithelial tissues. Since GSH levels have been measured in whole lungs, an increase
of GSH in (sub-) epithelial tissues may have been obscured. Finally, the GSH-
donors may not have entered the tissue, but instead may have remained in the
epithelial lining fluid. In the protocol in which GSEt was administered in
combination with methacholine challenges, the broncho-alveolar lavage had
probably washed away most of the GSEt.
OVA challenges consistently increased BAL cell counts in the sensitized mice but,
although such an inflammatory cell influx has been related to oxidative stress (8, 9),
anti-oxidant treatment around the time of each OVA challenge did not change BAL
cell numbers in our experiments. This may also be related to an absence of oxidative
stress during the allergen challenge as indicated by the lack of GSH-depletion in the
lungs (figure 12). In view of the evidence for an oxidative imbalance in a guinea pig
model of allergic asthma (chapters 4 and 5), as well as in asthmatics (2, 10-13), the
role of oxidative stress in the recruitment of inflammatory cells to the airways may
be smaller in mice as compared to guinea pigs and humans.
It is concluded that the decrease in airway contractility in mice when GSEt was
given in combination with a contractile agonist is in line with earlier experiments in
guinea pigs. However, the murine model lacks an early asthmatic response and
concomitant GSH depletion in the lungs, while these features are both prominent in
guinea pigs. In view of the presence acute asthmatic responses in humans and the
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increasing evidence for a role of oxidative stress in asthmatics, guinea pig models
may be more suitable than murine models to study the relation between oxidative
stress and allergic asthma.
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This thesis has demonstrated a role for GSH in relaxing airway smooth muscle, as
well as in moderating airway contractions. Although only a small number of
researchers have looked at GSH from a perspective of regulation of smooth muscle
tension, some data suggest a role for GSH in this area. Cheung et al. demonstrated
in 1997 that GSH could dose-dependently relax coronary arteries (1). Conversely,
GSH deficiency is associated with impaired relaxation. For instance, a high-
cholesterol diet was reported to decrease vascular GSH levels in rabbit aorta in
parallel with decreased responses to relaxing agents (2). Moreover, similar effects
were produced by an inhibitor of GSH reductase or a thiol-oxidizing agent, and
relaxations could be partially restored by GSEt (2). In another study, GSH-depletion
by inhibition of its synthesis led to hypertension in rats (3). This effect could be
mitigated by concomitant administration of the vitamins C and E. In line with these
reports, BSO-induced GSH depletion has produced arterial narrowing in rats (4).
While these papers point to a role of GSH in maintenance of vascular tone, the
evidence for similar effects in the airways is less abundant and more indirect. The
oxidizing agent, t-butylhydroperoxide, caused dose-dependent contractions in
human bronchial muscle in vitro, which could be prevented by NAC, an antioxidant
and GSH-precursor (5). A role of GSH as a protector against bronchoconstriction in
asthmatics is suggested by a study that demonstrated an increasing odds ratio for
asthma with increasing use of acetaminophen (6), an agent that depletes GSH in
lungs of animals (7).
The GSH-induced decrease in tracheal tension is mediated by potassium channels
The mechanism(s) via which GSH relaxes smooth muscle or moderates its
contractions are still elusive. Several mechanisms have been addressed in the studies
mentioned earlier. In the study by Cheung et al. (1), GSH-induced relaxations of
coronary arteries could be attributed to the smooth muscle relaxant, nitric oxide
(NO), and its biochemical target, soluble guanylyl cyclase (sGC).
Indeed, GSH and other thiols can bind to NO (8, 9), thereby enhancing the half-life
and bioavailability of the latter compound (10). Thus, after observing GSH-induced
relaxations in perfused isolated trachea tubes of guinea pigs (chapter 3), an attempt
was made to prove the involvement of NO. Increased nitrite concentrations in the
efferent perfusate suggested mediation by NO, since nitrite is a stable NO
breakdown product (11). However, despite the GSH-induced increased nitrite levels
in the trachea effluent, scavenging nitric oxide or using an inhibitor of sGC did not
decrease GSH-induced relaxations; this suggests that GSH-induced relaxation of
smooth muscle cells in the trachea is caused by a different mechanism as compared
to vascular tissue. In addition, the findings in chapter 3 indicate that relaxations that
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are paralleled by increased nitrite levels are not necessarily NO-mediated. Indeed,
the increased nitrite levels described in chapter 3 appeared to be an epiphenomenon.
This phenomenon could be accounted for by a pathway presented by Singh et al.
(12), in which the reaction between GSH and GSNO yields nitrite without an
involvement of NO, in the presence of oxygen. Since the oxygen tension was high
in the Krebs perfusion buffer, this pathway is likely to have occurred in the
experiments described in chapter 3. The presence of nitrosylated cysteine residues in
proteins and smaller thiols in the tracheal wall is very likely, because the tracheas
were isolated from healthy guinea pigs and because the tracheal epithelium, which is
an important source of NO (13), was removed shortly before the experiments. GSH
would then have liberated NO from these stores in a reaction that did not permit NO
to decrease trachea tension.
The involvement of potassium (K+-)channels in the relaxation of smooth muscle by
GSH (chapter 3) is supported by some comparable studies in which other
antioxidants were used. For instance, the antioxidant, ascorbic acid, was shown to
induce vasodilation in human veins in vivo. This effect could be blocked by the non-
selective K+-channel blocker, quinidine, but not by the specific blocker of ATP-
dependent K+-channels, glibenclamide (14). Likewise, a mimetic of the antioxidant
systems, superoxide dismutase and catalase, was reported to protect the
acetylcholine-induced relaxation of rat aortic rings from inhibition by superoxide.
This protective effect was inhibited by glibenclamide or the non-selective K+-
channel blocker, TEA (15). Furthermore, reducing agents, including GSH, increase
the open probability of Ca2+-activated K+-channels (16, 17), be it in clamped inside-
out membrane patches, and with administration of GSH at the cytosolic side. In the
experiments described in chapter 3, extracellular GSH may have increased cytosolic
GSH via an active uptake mechanism. There is indeed some evidence for the
presence of γ-glutamyl transpeptidase in the membrane of guinea pig trachea
smooth muscle cells (18), the enzyme that mediates GSH transport into the cell.
However, the almost immediate decrease of tracheal tension upon addition of GSH
to the organ baths would implicate a very high turnover rate.
The identification of the exact subtypes of K+-channels involved in the experiments
described in chapter 3 requires further experiments with selective K+-channel
inhibitors.
Allergen-induced oxidative stress in the lungs
It was unclear whether the studies on perfused tracheas were indicative of actions of
GSH in isolated lungs or in vivo. Notably, studies described in chapter 4 clearly
demonstrated that an EAR in guinea pigs in vivo is paralleled by oxidative stress as
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indicated by decreased lung GSH levels, increased GSSG levels and hence a
disturbed balance between reduced and oxidized glutathione. These data strongly
suggest that oxidative stress is a feature of an EAR. More evidence for that has been
provided in chapter 5, where it was demonstrated that the indicators of oxidative
stress, 8-iso-prostaglandin F2α (8-isoPGF2α) and thiobarbituric acid reactive
substances (TBARS), were increased in perfusate of isolated lungs during an EAR.
The source of oxidative stress is still elusive. Infiltrated leukocytes are the primary
source of reactive oxygen species during an inflammatory reaction (19), and are
thought to be responsible for the oxidative stress in the lungs of asthmatics (20, 21).
However, during the very first EAR, which was investigated in the models of
allergic asthma in chapters 4 and 5, leukocytes had not yet been recruited to the
lungs. Possible other candidates for the generation of oxidative stress are the
resident leukocytes, mast cells and macrophages. Indeed, it has been shown that
histamine release by isolated and stimulated mast cells is accompanied by an
increase in TBARS (22). Furthermore, activated macrophages are a well-established
source of ROS in the lungs (23) and in an EAR, mast cell-derived TNF-α may
activate macrophages to produce ROS (24, 25).
Regardless of its source, the oxidative stress can modulate airway contractility in at
least two ways. It can either alter the formation of relaxing or contractile mediators,
or modulate the responsiveness of smooth muscle to these mediators.
Modulation of the formation of contractile mediators by oxidative stress
Regarding oxidant effects on the formation of contractile mediators, histamine
release from cultured rat mast cells reportedly requires oxidation of arachidonic acid
by oxygen-centered free radicals (26). In addition, hydrogen peroxide has induced
histamine release by isolated mast cells (27). An important group of contractile
mediators are leukotrienes (28), which are generated from arachidonic acid by
lipoxygenases. Interestingly, a number of classes of lipoxygenase inhibitors are
antioxidative agents that act via reduction of the non-heme iron of the enzyme (29-
32). Another arachidonic acid-derived product, largely formed non-enzymatically, is
8-iso-PGF2α. Its formation requires reactive oxygen species; accordingly, this
compound was mentioned earlier in this chapter as an indicator of oxidative stress.
However, it is also a potent airway contractant of animal and human airways (33-
35).
The fact that the production of the above-mentioned contractile mediators is
associated with oxidative stress suggests that their formation can be inhibited by
antioxidants, possibly including GSH. In the case of cysteinyl-leukotrienes,
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however, it should be noted that GSH itself is a substrate for the formation of these
compounds; therefore, supplementing GSH may actually promote, rather than
inhibit, leukotriene synthesis. Since leukotrienes could not be measured reliably
(chapter 5), no final conclusions regarding the influence of putatively UWPC-
increased GSH levels on leukotriene formation could be drawn. Similarly, an
inhibitory effect of GSH on histamine levels in the lung could not be substantiated.
Possibly, a lower flow rate of the perfusion buffer would increase the chance that
mediators can be detected reliably. In contrast to leukotrienes and histamine, 8-iso-
PGF2α could be detected unambiguously (chapter 5). Although increased levels of 8-
iso-PGF2α confirmed the presence of oxidative stress during an EAR, this increase
was not diminished by feeding UWPC that enhanced liver GSH levels. As discussed
in that chapter, the failure of UWPC to decrease 8-iso-PGF2α levels may be due to
the dual action of GSH on 8-iso-PGF2α synthesis. GSH as an antioxidant may inhibit
all oxidative steps in the pathway of 8-iso-PGF2α formation, except the last one.
Since the last step involves the reduction of a bicyclic endoperoxide (36), the
formation of 8-iso-PGF2α can be promoted by GSH (figure 1) (37). Thus, assuming
that UWPC had increased lung GSH, as demonstrated in liver, the above
mechanisms may have resulted in a neutral effect of UWPC in 8-iso-PGF2α
formation.
Modulation of the formation of relaxing mediators by oxidative stress
In addition to affecting the formation of airway contractile mediators, GSH may
influence the formation of airway relaxants. For instance, it is well known that
reactive oxygen species, especially superoxide, can substantially diminish the
bioavailability of the (airway) smooth muscle relaxant (38), NO (39). Accordingly,
several antioxidants can enhance the relaxant effect of NO, although an interference
with the inhibitory action of ROS is not proven for all of them (40). As described
earlier in this chapter, GSH may not only prevent the breakdown of NO by
scavenging ROS, but it can also bind to NO, thus forming GSNO as described by
Gaston (10). GSNO is more stable than genuine NO. Thus, both scavenging of ROS
and binding of GSH to NO can enhance the bioavailability of NO as a relaxant
mediator. PGE2 was the only relaxant mediator that could be measured reliably in
the perfusates of isolated tracheas (chapter 3) and lungs (chapter 5), although results
of other attempts (chapter 4) were ambiguous and were, therefore, not included.
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Figure 1. Formation of oxidation products of arachidonic acid. While reaction a is a
rearrangement, reaction b is a reduction step that is promoted by GSH (34).
Malondialdehyde and 4-hydroxynonenal are thiobarbituric acid-reactive substances
(TBARS). PLA2, phospholipase A2.
GSH did not alter PGE2 levels in the effluent from tracheal tubes, but the data in
chapter 5 show that PGE2 was decreased after UWPC-feeding. Provided that UWPC
had enhanced lung GSH levels, these data indicate that GSH decreased PGE2
formation.
These results are at variance with data from Hempel et al., who have shown that
oxidative stress decreased PGE2 synthesis, and that GSH prevented this decrease
(41). In contrast, other data have indicated an inverse relation between PGE2
synthesis and GSH levels in microsomal fractions from goat lungs (42). Moreover,
it has been suggested that PGE2 production is stimulated by oxidative stress (43) and
inhibited by an ROS-scavenger (44). The findings in chapter 5 would be line with
the latter three reports.
As mentioned in chapter 5, it is also possible that the altered PGE2 production was
not a direct consequence of altered GSH levels, but rather of the degree of airway
contractions. Notably, the severe airway contractions following allergen challenge
were paralleled by markedly increased PGE2 production as compared to the saline-
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challenged animals. Similarly, the smaller airway contractions UWPC feeding may
have led to less PGE2 production.
Alteration of smooth muscle responsiveness by oxidative stress
A third mechanism by which oxidative stress may alter smooth muscle contractions
is by influencing the responsiveness of smooth muscle to mediators. For instance, it
has been reported that the non-enzymatic oxidation product of arachidonic acid, 8-
iso-PGF2α, increases the sensitivity to other contractile agents (45). The mechanism
behind this effect is still unclear; however, a study on another lipid peroxidation
product, 4-hydroxynonenal, provides a clue. The altered contractile responses to
other agents as induced by this compound have been attributed to alkylation of thiol
groups (46). Therefore, it is not unlikely that potentiated contractions to other
mediators as caused by 8-iso-PGF2α were accompanied by alkylation of thiol groups
as well. Since GSH potently protects tissues against alkylating agents (47), it may
likewise attenuate the effects of 8-iso-PGF2α by this action. This may also explain
the paradox that the UWPC-induced decrease in lung contractility was paralleled by
an increase in iso-PGF2α. The finding that GSH depletion increased airway
contractility to histamine accordingly may be explained by a lack of GSH-mediated
protection against alkylation or oxidation of proteins that mediate smooth muscle
contractility. Similar mechanisms may underlie the relaxing effects of GSH in the
trachea (chapter 3). The finding that K+-channels mediate these relaxations and the
fact that thiol-modifying agents regulate K+-channel activity suggest that GSH may
protect functional sulfhydryl groups in K+-channels against oxidative modification.
The source of the oxidative stress in these experiments may have been the 95% O2-
containing gas mixture used to aerate the Krebs buffer. Indeed, it was recently
shown that levels of GSH in rat livers were substantially decreased after 4 h of
perfusion with Krebs buffer aerated with 95% O2, as compared to normoxic gas
(21% O2). Addition of NAC to the buffer prevented the decrease of liver GSH and
disturbance of the GSH/GSSG ratio (48). These data suggest that aeration of
perfusion buffers with a gas mixture containing 95% O2 as commonly practiced in
organ bath studies can cause unwanted artifacts affecting smooth muscle tension.
Species differences
Whereas respiratory allergen challenge of sensitized guinea pigs induced an
unambiguous EAR paralleled by a clear decrease in GSH levels (chapter 4),
respiratory challenge of sensitized mice with the same allergen failed to show either
of these effects (chapter 6). The presence of a symptomatic EAR in the guinea pig
and its absence in the mouse were expected features of the animal models; however,
the fact that the presence and absence of an EAR coincided with the presence and
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absence of lung GSH depletion was unexpected, and suggests that oxidative stress is
a contributing factor of symptomatic EARs.  Oxidative stress during allergen
challenge, however, is apparently not required for the development of non-specific
airway hyperresponsiveness upon allergen challenge, given that both species display
this phenomenon. Solid evidence for this notion requires additional studies in guinea
pigs in which oxidative stress of the EAR is prevented by exposing the animals to
allergen in combination with a GSH supplement.
The fact that asthmatics display a symptomatic EAR may underline the importance
of oxidative stress in the pathology of asthma. Indeed, levels of the indicator of
oxidative stress, 8-iso-PGF2α (49), were found to be increased in exhaled air of
asthmatics (50), and 8-iso-PGF2α plasma levels correlated with disease severity in
mild asthmatics (51). Moreover, in atopic asthmatics, inhaled allergen challenge
increased the urinary excretion of 8-iso-PGF2α (52). The apparently crucial role of
oxidative stress in the guinea pig model, but not in the murine model, of allergic
asthma as described in this thesis, suggests that guinea pigs are a better species to
study allergic asthma than mice, at least when addressing the role of oxidative stress
and therapeutic potential of antioxidants in the context of this disease.
Prophylactic GSH administration
Since asthmatic reactions in humans are accompanied by oxidative stress, asthmatic
symptoms may be prevented or relieved by increasing lung levels of antioxidants
like GSH. Studies in chapter 6, however, showed that this is not easily achieved.
The delivery of aerosols with GSH donors around allergen challenges did not
increase tissue levels of GSH in the lungs. These results could be explained by the
time point at which GSH levels were assessed in the lungs (24 hours after the last
aerosol with a GSH precursor). In that respect, our data are consistent with those of
Buhl et al., who showed that the increase of GSH levels in the epithelial lining fluid
after application of a GSH aerosol lasted less than two hours (53). In humans, too,
only a transient increase in GSH + GSSG was observed in the epithelial lining fluid
after a GSH aerosol (54). These studies suggest that GSH or its donors should be
delivered relatively frequently to cause a lasting increase in GSH levels. Although
some studies have addressed the kinetics of GSH after an aerosol by assessing GSH
levels in epithelial lining fluid, the effects on GSH levels in lung parenchyma
remain to be determined. This is especially important since most inflammatory cells,
and, therefore, probably most of the oxidative stress, are located in the lung
parenchyma rather than in the airway lumen. Despite the poor knowledge regarding
the kinetics of GSH after the administration of GSH or its donors via aerosols, this
mode of administration has yielded some promising results. For instance, GSH
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nebulization has decreased non-specific airway contractions in asthmatics (55) and
airway obstruction in COPD patients (56). Additionally, a decrease of inflammatory
cell activity in idiopathic pulmonary fibrosis patients was demonstrated in a study
by Borok et al. GSH aerosols in these patients attenuated the increased spontaneous
superoxide release by their macrophages (54). These studies reported that
administration of thiol compounds had no adverse effects. Only one study has
reported bronchoconstriction in mild asthmatics upon administration of GSH by
aerosol (57). This study, however, used very high concentrations (0.5 M) of GSH.
Alternative methods to increase lung GSH levels include oral administration of GSH
precursors. A GSH precursor that has been used in the context of lung diseases for
over 2 decades is the mucolytic, N-acetylcysteine (NAC). Although the airways
provide an excellent route for topical administration, NAC is usually given orally
(58). However, high oral doses of NAC (300 mg three times per day, or 600 mg
once daily), did not increase cysteine concentrations in airway lining fluid (59, 60).
As far as known, effects of oral NAC administration on GSH levels in lung
parenchyma have not been assessed. It is not impossible that these are increased,
since oral administration of NAC was found to increase plasma levels of GSH (59)
and since lung tissue appeared capable of utilizing plasma GSH (61, 62). However,
there is currently no evidence to prove that this route effectively increases GSH
levels in lung parenchyma.
UWPC
An alternative to oral NAC administration to increase tissue GSH levels may be
provided by an undenatured whey protein concentrate, UWPC. In guinea pigs, daily
feeding UWPC for 24 days increased liver total glutathione levels by 20% (chapter
5). This figure agrees well with results of a study in HIV-infected patients (63), in
whom UWPC, given as a food supplement, increased plasma GSH levels by 24%.
Similar as in the study in chapter 5, indicators of oxidative stress were not changed
in the UWPC-treated HIV-positive patients. This was also found in patients who
received a different brand of whey-based food supplement that induced a 45%
increase in plasma GSH levels (63). The absence of improved clinical parameters in
that study contrasts with a case report describing a woman with obstructive lung
disease (64). Upon taking UWPC, her plasma GSH levels increased twofold, and the
lung function parameters, FEV1 and FVC, were improved.
The fact that in guinea pigs a modest increase in GSH levels was associated with a
significant and substantial decrease in allergen-induced lung contractility is
surprising. The patent application of UWPC claims that it is rich in several vitamins
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B, which would promote the reduced state of GSH. If this is true, UWPC would not
only enhance GSH levels, but also sustain the reduced state of the molecule.
However, there is no literature supporting this notion.
The merits of UWPC in the model described in chapter 5 and its relevance to human
asthma, may be more solid when reliable data on GSH and GSSG levels in the lungs
will be available. Thus, it should be investigated whether UWPC diminishes the
decrease in lung GSH in sensitized guinea pigs after allergen challenge in vivo.
Inflammation
ROS
Oxidative stress
Hyperoxia
Antioxidants
GSEt,
NAC
(UWPC)
GSH
Sulfhydryl
oxidation
Contractile
mediators
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airway
contractility
NO
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+
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Figure 2. Outline of the major mechanisms regarding GSH as a moderator of airway
contractility as addressed in this thesis. Oxidative stress can result either from an
inflammatory reaction via the production of ROS in vivo, or from hyperoxic
conditions in organ baths. The oxidative stress could lead to increased airway
contractility via oxidation of critical sulfhydryl groups, increased formation of
contractile mediators, and / or other, yet unidentified mechanisms. GSH may interfere
with these events and thus prevent or decrease increased airway contractility. Several
GSH enhancing compounds, like GSEt, NAC, and possibly UWPC, may therefore
have therapeutic potential in asthma.
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In conclusion, the data presented in this thesis indicate that GSH protects the
airways against excessive constriction, probably by virtue of its antioxidant
properties. An outline of the major mechanisms and limitations in scientific
evidence as addressed in this thesis is presented in Figure 2. In view of the presence
of increased airway contractility and the accumulating evidence of oxidative stress
in asthma, the use of GSH to alleviate asthmatic symptoms certainly warrants
further research.
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Allergisch astma is een longaandoening waaraan wereldwijd 5% van de
volwassenen en 10 tot 15% van de kinderen lijden. Een belangrijk kenmerk van
allergisch astma is een chronische ontsteking van de luchtwegen. De
ontstekingscellen die hierbij betrokken zijn produceren zogenaamde reactieve
vormen van zuurstof (afgekort ROS, naar de Engelse term reactive oxygen species).
Dit zijn zuurstofverbindingen die aggressiever zijn dan moleculair zuurstof en
daarom zeer geschikt voor de verdediging van het lichaam tegen ziekteverwekkers.
De productie van ROS is dan ook een normaal verschijnsel tijdens een infectie. Het
lichaam zelf wordt tegen ROS beschermd door antioxidanten. In bepaalde gevallen
brengen ROS toch schade toe aan het eigen weefsel. Dit kan het gevolg zijn van een
excessieve productie van ROS door het ontsporen van het afweersysteem, of door
een tekort aan antioxidanten; waarschijnlijk treedt vaak een combinatie van beide
op. Deze disbalans, die kan leiden tot schade aan en dysfunctie van weefsels en
organen, wordt oxidatieve stress genoemd. Er komen steeds meer aanwijzingen dat
oxidatieve stress een rol speelt in de pathologie van astma.
Een in het lichaam - en ook in de longen - veelvoorkomend antioxidans is
glutathion. Wanneer gereduceerd glutathion (de normale vorm van glutathion)
optreedt als beschermer van het weefsel tegen oxidatieve stress wordt het omgezet in
geoxideerd glutathion; glutathion wordt dus opgeofferd teneinde het weefsel tegen
oxidatie te beschermen. Algemeen wordt de balans tussen gereduceerd en
geoxideerd glutathion (GSH resp. GSSG) beschouwd als een indicator voor
oxidatieve stress.
Een tweede kenmerk van allergisch astma is een overmatige vernauwing  van de
luchtwegen (luchtweghyperreactiviteit). De diameter van de luchtwegen kan worden
verkleind door autonoom, zogenaamd glad spierweefsel. Samentrekking (contractie
of constrictie) van glad spierweefsel in de luchtwegen kan teweeggebracht worden
door aspecifieke prikkels, zoals koude lucht of mist, of door specifieke prikkels,
zoals de ontstekingsmediator histamine. Er wordt vaak een verband gelegd tussen de
ontsteking van de luchtwegen en luchtwegconstrictie, maar hoe de twee precies
gerelateerd zijn is vooralsnog onduidelijk.
In dit proefschrift is de vraag aan de orde gesteld of de oxidatieve stress als gevolg
van luchtwegontsteking verband kan houden met constrictie van de luchtwegen
tijdens astma.
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Om contracties van de luchtwegen te bestuderen worden vaak stukjes luchtpijp
(trachea) uit dieren geïsoleerd en in leven gehouden in een orgaanbad, waarin de
spiercontracties bepaald kunnen worden. In hoofdstuk 2 wordt de bevinding
beschreven dat het hogere deel van de luchtpijp (het proximale trachea-segment) van
de cavia sterker op een contractiele prikkel reageert dan het lagere (distale) segment.
Tijdens de zoektocht naar een verklaring voor dit verschijnsel is onderzocht of GSH-
spiegels in de proximale trachea verschilden van die in de distale trachea. Dit bleek
niet het geval te zijn, zodat het onwaarschijnlijk is dat GSH iets te maken heeft met
de differentiële contractiliteit van de proximale en distale trachea.
Dat GSH wel degelijk in staat is om de contracties van de trachea te moduleren
blijkt uit hoofdstuk 3. Hierin is beschreven dat het spierweefsel van trachea's in een
orgaanbad ontspande (relaxeerde) door blootstelling aan GSH. Dit proces was dosis-
afhankelijk - d.w.z. hoe meer GSH, des te meer relaxatie - en kon geremd worden
door een remmer van kaliumkanalen. Kaliumkanalen kunnen de polariteit, en
daarmee het vermogen tot samentrekken, van spiercellen mede regelen. Een ander
mogelijk mechanisme dat is onderzocht, is een interactie van GSH met de door het
lichaam zelf geproduceerde gladde-spier-ontspannende stof, stikstofoxide (NO). NO
zelf is zeer instabiel, maar door te binden aan GSH kan het zijn levensduur en
biologische beschikbaarheid vergroten. De hoeveelheid NO wordt vaak gemeten
door het stabiele afbraakproduct van NO, nitriet te bepalen. Inderdaad wezen
metingen uit dat nitrietconcentraties in het orgaanbad toenamen op het moment dat
GSH aan het orgaanbad werd toegevoegd en de trachea's ontspanden. Het leek er dus
op dat de door GSH veroorzaakte relaxaties gemediëerd werden door NO uit de
trachea. Dat dit slechts schijn was, bleek uit twee vervolgexperimenten. In de eerste
plaats werden de door GSH geïnduceerde relaxaties niet tegengegaan door een
remmer van het enzym guanylaatcyclase, dat nodig is voor ontspanning van glad
spierweefsel door NO. In de tweede plaats bleek PTIO, een stof die NO bindt en
onwerkzaam maakt, ook geen effect te hebben op de spierontspannende werking van
GSH. Blijkbaar vond tijdens de in dit hoofdstuk beschreven experimenten wel een
interactie tussen GSH en NO plaats, maar mediëerde NO de door GSH
teweeggebrachte relaxaties niet. De verhoogde nitrietconcentraties die eerder op
betrokkenheid van NO bij de relaxaties leken te wijzen, kunnen verklaard worden
met een model dat onlangs in de literatuur gepresenteerd is. Dit model stelt een
reactie voor waarin nitriet, in aanwezigheid van GSH en zuurstof, direct gevormd
wordt uit GSNO, het reactieproduct van GSH en NO.
Bij astmatici is het weefsel dat de binnenkant van de luchtwegen bekleedt, het zgn.
epitheel, vaak beschadigd. Deze beschadiging verklaart een deel van de
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hyperreactiviteit van de luchtwegen van astmatici voor contractiele prikkels. Om
deze situatie te imiteren, worden vaak experimenten gedaan met stukjes trachea
waarvan het epitheel verwijderd is. Om hun vermogen tot samentrekken te
bestuderen worden de eerder beschreven orgaanbaden gebruikt. Net als luchtwegen
van astmatici zijn epitheelloze trachea-segmenten hyperreactief ten aanzien van
contractiele mediatoren; ze contraheren meer dan intacte trachea-segmenten. Het
laatste experiment in hoofdstuk 3 toonde aan dat GSH niet alleen trachea's kan
relaxeren, maar dat GSH ook de hyperreactiviteit van epitheelloze trachea's voor ca.
50% kan tegengaan.
Uit het bovenbeschreven hoofdstuk blijkt dus dat GSH de luchtwegen kan relaxeren
en ze bovendien kan beschermen tegen hyperreactiviteit. In het licht van deze
bevindingen is het interessant om te weten of er in de longen van astmatici minder
GSH voorkomt dan in die van gezonde mensen. Omdat het nauwelijks haalbaar is
om GSH in longweefsel van astmatici te meten, is voor de beantwoording van deze
vraag een diermodel voor allergisch astma gebruikt. GSH en GSSG zijn in de longen
van cavia's gemeten op het moment dat ze een aanval van allergisch astma
ondergingen (hoofdstuk 4). Inderdaad bleek dat GSH-spiegels in de longen van
"acuut astmatische" dieren ca. 40% lager waren dan het geval was bij controledieren.
Daarbij waren GSSG-spiegels juist verhoogd; in de longen van deze dieren was dus
blijkbaar sprake van oxidatieve stress.
In het kader van deze bevindingen werd in dit hoofdstuk verder onderzocht of het
toedienen van extra GSH aan de longen van astmatische dieren een aanval van
allergisch astma kon verlichten. Om deze vraag te beantwoorden werden
vrijgeprepareerde cavialongen doorspoeld met perfusievloeistof, terwijl hun
contractie werd gemeten. Wanneer in deze geprepareerde longen een astmatische
aanval werd opgewekt, kon een toename in de contractie van de luchtwegen
waargenomen worden. Inderdaad waren deze contracties minder hevig wanneer de
longen via de perfusievloeistof werden voorzien van extra GSH. Nog meer bewijs
voor het belang van GSH in de luchtwegen kwam van een ander experiment in dit
hoofdstuk, waarin werd aangetoond dat geïsoleerde longen, afkomstig van cavia's
waarin GSH-spiegels kunstmatig verlaagd waren, hyperreactief waren ten aanzien
van de contractiele mediator histamine.
Omdat het toedienen van stoffen aan geïsoleerde longen via een perfusievloeistof
een handige route is in het laboratorium maar voor astmapatienten niet reëel is, is in
hoofdstuk 5 gezocht naar geschikte mogelijkheden om GSH bij astmatici te
verhogen. Orale toediening van GSH zelf biedt geen soelaas omdat het de longen
niet bereikt. Er bestaan echter voedingssupplementen op basis van wei (een
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bijproduct van de kaasbereiding) waaraan een GSH-verhogend effect wordt
toegeschreven. In hoofdstuk 5 wordt beschreven hoe zo'n dieet is getest op het
vermogen om een astmatische aanval te verlichten in hetzelfde model voor
allergisch astma als beschreven in hoofdstuk 4. Inderdaad waren de astmatische
contracties in longen van met wei bijgevoerde cavia's minder ernstig dan het geval
was bij longen van met een controlevloeistof bijgevoerde dieren. Dat dit te danken
was aan een verhoging van GSH-spiegels is waarschijnlijk, omdat de GSH-spiegels
in de levers van behandelde dieren hoger waren dan die van controledieren. Om het
werkingsmechanisme van het supplement nader te onderzoeken is getracht te
bewijzen dat in de longen van met wei gevoerde dieren minder oxidatieve stress
optrad dan in de longen van controledieren. Hoewel twee relevante indicatoren
aangaven dat de allergische aanval zelf, zoals verwacht, oxidatieve stress deed
toenemen, kon de gunstige werking van het voedingssupplement niet teruggevoerd
worden op een vermindering ervan. Evenmin kon worden bewezen dat het
voedingssuplement leidde tot een verminderde vorming van contractiele mediatoren
of een verhoogde vorming van relaxerende mediatoren. Het voedingssupplement
lijkt dus een gunstige werking op de ernst van een astmatische aanval te hebben,
maar het achterliggende mechanisme is nog onduidelijk.
De bovenbeschreven bevindingen hebben alle betrekking op een model waarin de
allereerste allergische aanval werd bestudeerd, terwijl bij astmatici meestal sprake is
van herhaalde blootstelling aan een allergische prikkel (allergeen). Om die situatie
beter te benaderen is in hoofdstuk 6 gebruik gemaakt van een model waarin de
luchtwegen van dieren (in dit geval muizen) herhaaldelijk worden blootgesteld aan
een allergeen. Bij aldus behandelde dieren zijn de luchtwegen ontstoken en
hyperreactief. Deze luchtweghyperreactiviteit wordt aan het eind van het experiment
bepaald door oplopende doses van de contractiele stof methacholine te laten
inhaleren en vervolgens hun luchtwegfunctie te meten. Met dit model is onderzocht
of geïnhaleerd GSH astmatische symptomen kan voorkomen of verminderen. De
inhalatie van GSH vond plaats tijdens of vlak voor elke blootstelling aan allergeen,
of gelijktijdig met het inhaleren van methacholine. Het bleek dat GSH de
luchtweghyperreactiviteit tegenging wanneer het werd geïnhaleerd tijdens de
blootstelling aan methacholine, en niet wanneer GSH gegeven werd tijdens
blootstelling aan allergeen. Bovendien leek GSH de ontsteking in de luchtwegen niet
effectief te bestrijden, want de hoeveelheid ontstekingscellen in het lumen (de
holtes) van de luchtwegen was niet verminderd na behandeling met GSH. Interessant
was bovendien dat GSH- en GSSG-concentraties in de muizenlong niet verstoord
waren tijdens blootstelling aan allergeen. Het lijkt er dus op dat blootstelling van
muizen aan allergeen niet leidt tot oxidatieve stress in hun longen, dit in
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tegenstelling tot de situatie in de cavialong. Omdat muizen, in tegenstelling tot
cavia's, ook geen symptomatische astmatische aanval doormaken tijdens
blootstelling aan allergeen, lijkt het erop dat oxidatieve stress en een acute
astmatische reactie aan elkaar gerelateerd zijn. Daarnaast blijkt uit dit hoofdstuk dat
de cavia geschikter is voor studies naar aspecten van oxidatieve stress in astma dan
de muis.
Concluderend wijzen de in dit proefschrift beschreven experimenten erop dat GSH
de luchtwegen kan beschermen tegen excessieve contracties zoals die zich bij astma
voordoen. De aanwezigheid van luchtweghyperreactiviteit en de toenemende
aanwijzingen voor oxidatieve stress bij astma rechtvaardigt nader onderzoek naar het
gebruik van GSH ter verlichting van astmatische symptomen.
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List of abbreviations
BAL Broncho-alveolar lavage
BSO D,R-buthionine-L-sulfoximine
Cys L-cysteine
EAR Early asthmatic reaction
Emax Maximum response
EPO Eosinophil peroxidase
GSEt Glutathione-ethyl ester
GSH Glutathione
GSNO S-nitrosoglutathione
GSSG Oxidized glutathione
GTN Glyceryl trinitrate
H2O2 Hydrogen peroxide
8-iso-PGF2α 8-iso-Prostaglandin F2α
MPO Myeloperoxidase
NAC N-acetyl-L-cysteine;
NEM N-ethyl maleimide
NO Nitric oxide;
O2.- Superoxide
OH. Hydroxyl radical
ODQ 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
OVA Ovalbumin
Penh Enhanced pause
PGE2 Prostaglandin E2
PTIO 2-Phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide
ROS Reactive oxygen species
RSNO S-nitrosothiol
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sGC Soluble guanylyl cyclase
SOD Superoxide dismutase
TBARS Thiobarbituric reactive substances
TEA Tetraethylammonium
UWPC Undenatured whey protein concentrate
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Stellingen behorende bij het proefschrift
Glutathione and airway function door Joris Kloek
1. Het gebruik van meerdere trachea-segmenten van hetzelfde dier voor de
bestudering van luchtwegreactiviteit met het oogmerk om proefdier-
besparend te werken, kan contraproductief uitpakken en verkeerde
conclusies in de hand werken.
Dit proefschrift
2. Voor de bestudering van oxidatieve stress bij astma is de cavia een
geschikter proefdier dan de muis.
Dit proefschrift
3. Het meten van totaal glutathion in de broncho-alveolaire lavage levert
onvoldoende informatie om een uitspraak te doen over de gevolgen van
oxidatieve stress in de longen voor de glutathion-huishouding.
Smith, L.J., M. Houston, and J. Anderson. 1993. Increased levels of glutathione
in bronchoalveolar lavage fluid from patients with asthma. Am Rev Respir Dis
147:1461.
4. De invloed van zuurstofspanning op antioxidant systemen van organen in
orgaanbaden verdient nadere bestudering.
Miralles, C., X. Busquets, C. Santos, B. Togores, S. Hussain, I. Rahman, W.
MacNee, and A.G. Agusti. 2000. Regulation of iNOS expression and glutathione
levels in rat liver by oxygen tension. FEBS Lett 476:253.
5. Het schrijven van een projectvoorstel is voor een promovendus minstens
even leerzaam als het uitvoeren ervan.
6. Kloeks zesde stelling: uiteindelijk toch houdbaar.
J.J. Kloek (1985) Over Werther geschreven…
J. Kloek (1941) Het begrip regressie
7. De kwalificatie 'typisch Nederlands', in misprijzende zin gebruikt, wordt
met name gebezigd door mensen die de aandacht willen vestigen op de
vermeende breedte van hun horizon.
8. De binnenvaart belichaamt al eeuwen de beste Betuwelijn.
9. Het stelselmatig maken van verre reizen om andere culturen te ontmoeten
ondergraaft op den duur de reden van deze reizen.
10. Het grote aantal witte jassen in ziekenhuiskantines suggereert dat veel
artsen meer waarde hechten aan status dan aan hygiëne.
